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CHAPTER 1 
 
STUDY OVERVIEW 
 
Chronic pain and substance abuse/dependence both cause substantial individual 
suffering and societal costs. Brooner (2008) states that “substance use disorders and 
chronic pain produce an impressive and strikingly similar range and number of negative 
effects on humans and society, and cause notable concerns and dilemmas…across the 
entire health care treatment system” (p. 485).  Although effective interventions for each 
of these conditions have been developed, chronic pain and substance misuse are often 
co-morbid.  Unfortunately, the field currently lacks guidelines for identifying chronic pain 
patients who are at high risk for prescription misuse and/or substance abuse, and there 
is a need for research to help clinicians understand who is most likely to misuse their 
prescriptions or other substances while receiving treatment for chronic pain (Turk, 
Swanson, & Gatchel, 2008). Identifying patients most at risk for developing prescription 
or substance use problems can lead to better targeting of substance abuse prevention 
and treatment among people with chronic pain.   However, research is limited on 
substance abuse, particularly prescription opioid misuse, within chronic pain 
populations.    
Notably, similar factors, such as trauma history and low social support, have 
been implicated in the development and maintenance of both chronic pain and 
substance abuse. The shared risk factors for the development of chronic pain and 
substance abuse highlight the need for further research into the relationship of chronic 
pain and substance abuse. The limited predictive factors applied to prescription opioid 
abuse in chronic pain patients is surprising given the breadth of personal, cognitive, and 
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emotional factors explored in the separate literatures on chronic pain and substance 
abuse. Prior research has examined, without conclusive results, the predictive factors of 
previous substance abuse, age, gender, and prior history of psychiatric diagnoses 
(Michna et al., 2004).  
Physicians treating chronic pain patients are in the difficult position of identifying 
any signs of prescription drug abuse and preventing abuse of other substances, yet 
they lack evidence-based guidelines to inform their decisions. Daily, physicians who 
treat chronic pain patients are forced to make decisions about whether medication is 
needed, whether the medication is effective, and whether there are any harmful effects 
of use. There are currently few factors guiding physicians’ decisions as to whether an 
individual patient may need additional regulation of pain medications because of risks. 
One study showed that people who are regularly prescribed opioids for the treatment of 
pain had increased rates of opioid and other substance abuse problems (Edlund, 
Sullivan, Steffick, Harris, & Wells 2007), and did not have improved pain relief, quality of 
life, or functional ability as compared to other pain patients not receiving medication 
(Eriksen et al., 2006). These findings suggest that there are serious risks associated 
with chronic prescription opioid use, and further research is needed.  
Research on prescription misuse and substance use in chronic pain patients has 
been limited in scope, likely due in part to researchers’ difficulties in defining 
prescription misuse and inaccuracy in self-report. As many of the previous research 
studies have been conducted using medical record review or conducted by individuals 
closely tied to the patients’ treatment, reporting of prescription misuse and substance 
use has likely been compromised. In clinical settings, gathering accurate information 
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about personal history, prescription misuse, and substance abuse can be critical to 
providing effective care. In research settings, gathering accurate information from 
participants is critical to the fidelity of a study and the usefulness of interpretations. 
Paper-and-pencil methods and clinician interviews—of varying skill and effectiveness—
are the most common methods of assessing this information, but the method used 
appears to influence outcomes. For example, Gerbert et al. (1999) found that primary 
care patients who completed a computerized form reported significantly more drug and 
alcohol risk behaviors than those in a standard interview condition. The method by 
which information is gathered from participants is known to significantly change the 
outcome of studies. Literature specific to methods by which information about 
stigmatized behaviors is gathered is still in its developmental phase, but much of the 
work has focused on the use of computerized programs for eliciting sensitive 
information (e.g., Newman et al., 2002) which may not be feasible to implement in direct 
patient care. Doctor-patient interactions are the most likely time to collect information 
about the risky behaviors of chronic pain patients in ongoing care, and these 
interactions are nearly always face-to-face. There is a need to develop and test 
methods to assess substance abuse and other stigmatized behaviors that can be easily 
employed in clinical settings.  
In this dissertation project, two major areas that have been inadequately studied 
within the chronic pain literature were examined. First, although research has identified 
several demographic and social factors that are implicated in the development and 
maintenance of both chronic pain and substance abuse, little research has been done 
on emotional risk factors, including a history of traumatic experiences and how one 
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regulates one’s emotions. Although many people have hypothesized that emotional 
factors contribute to both chronic pain and substance misuse, this needs to be tested in 
patients who are co-morbid for both. The second area that was studied is the method by 
which sensitive information, such as prescription misuse, substance abuse, and trauma 
history, is gathered. There is a need to experimentally test clinically feasible methods of 
enhancing patients’ reports of such stigmatized behaviors, and interviews using 
enhanced communication techniques may accomplish this goal.  
Overall, this study had several aims of substantial theoretical and practical 
importance to the fields of medicine and psychology. The first goal was to determine 
which demographic, pain-related, cognitive/social, and stress/emotional factors predict 
the abuse of prescription or other substances among patients in treatment for chronic 
pain. The second goal was to test whether knowledge of factors related to stress and 
emotion regulation (low emotional awareness and expression, high experience and 
impact of lifetime trauma) predict prescription and substance misuse beyond more 
routinely assessed and established factors. The third goal was to compare different 
methods of eliciting disclosure of stigmatized information (misuse of prescription 
medication, use of alcohol/drugs, and experience of stressful events or traumas), and 
test whether an innovative, clinically sensitive interview protocol will enhance disclosure 
beyond a traditional interview and a questionnaire. 
To address these aims, patients with chronic pain who were receiving opioid 
treatment through a local pain management clinic were recruited. Participants 
completed most of the predictor measures (i.e., demographic, pain, cognitive/social, and 
emotional measures) in paper-and-pencil format, but were randomized to provide 
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information about drug use and trauma history in one of three formats: a written (non 
face-to-face) paper-and-pencil questionnaire, standard face-to-face clinical interview, or 
an enhanced interview, in which the interviewer followed a scripted method for 
encouraging further disclosure (e.g., normalizing the occurrence of prescription 
misuse/trauma, discussing concerns of confidentiality in detail, etc.).   
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CHAPTER 2 
LITERATURE REVIEW 
 
Chronic pain is defined as “pain that extends beyond the period of tissue healing 
or with low levels of identified pathology that are insufficient to explain the presence 
and/or extent of pain” (Jacobsen & Mariano, 2001). Chronic pain can be initiated by a 
range of triggers (e.g., disease, injury), but it is maintained or aggravated by a variety of 
additional psychological, behavioral, and environmental factors such as coping, stress, 
decreased activity, and legal disability status (Visser, 2006). Chronic pain impacts the 
lives of over 75 million people in the United States. It has a major impact upon our 
health care industry, as chronic pain patients need increasing care as they try to 
manage this debilitating condition (Becker, Fiellin, & Desai, 1997). Chronic pain is a 
leading cause of disability and interference with job performance. There are limited 
treatment options used for chronic pain patients. Traditional treatments for chronic pain 
include the use of analgesic medications, but chronic pain is rarely fully controlled by 
analgesics (Eriksen, Sjogren, Bruera, Ekholm, & Rasmussen, 2006). A statement in the 
Research Reports Series: Prescription Drugs: Abuse and Addiction highlights the 
common dilemma of treatment providers in the field of chronic pain: “How to adequately 
relieve a patient’s suffering, while avoiding the potential for that patient to become 
addicted to the pain medication. (pg. 7)” 
Given the evidence that chronic pain is rarely controlled fully by analgesic 
medications, we also know that patients may use other substances that are not 
prescribed to try to manage pain on their own (Brennan, Schutte, & Moos, 2005). 
Individuals with chronic pain have increased rates of substance abuse and psychiatric 
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disorders (Twillman, 2007; Weisberg & Boatwright, 2007). The elevated rates of 
substance abuse within chronic pain populations provides further support for the need 
to develop better predictive models for abuse potential within chronic pain patients.  
Like chronic pain, substance abuse and dependence also have a profound 
impact on the lives of many people. Substance abuse and dependence are related to 
significant work and relationship disability, are comorbid with other psychiatric illnesses, 
are associated with lower quality of life, and are linked to serious health complications 
(Hser, Hoffman, Grella, & Anglin, 2001; Maddux & Desmond, 1992; Marmorstein, 
Iacono, & Malone, 2010; Research Society on Alcoholism, 2011). Much of the concern 
about the potential abuse of prescription opioids has been spurred by concerns over the 
non-medical use of prescription opioids, such as youth who have not been prescribed 
the medication, the street sales of prescription drugs, and so on. The non-medical use 
of prescription opioids has led to mounting concerns about preventing diversion of 
prescriptions and identifying individuals most at risk of abusing those prescriptions. 
Non-Medical Use/Abuse of Prescription Opioids 
Becker, Sullivan, Tetrault, Desai, and Fiellin (2008) found that non-medical use of 
prescription opioids was 4.5% and increasing, based on data from the 2002-2004 
National Survey on Drug Use and Health. Within this 4.5%, some individuals were 
misusing prescriptions provided for medically-valid reasons, and some individuals were 
using the opioids without any medical need. Blanco et al. (2007) found similar results 
using data from the National Longitudinal Alcohol Epidemiologic Survey and National 
Epidemiologic Survey on Alcohol and Related Conditions. Blanco et al. compared data 
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from 1991 and 2001 and found that non-medical use of prescription opioids had 
increased 53% over that time period.  
The fear of the significant impact that abuse of drugs has on a community, 
coupled with the increasing use of non-prescription opioids, has raised concern within 
the medical community about the appropriateness of prescribing these medications to 
patients with chronic pain (Erikson, 2008). Despite this recent interest in the non-
medical use of prescription opioids, the long-term medical use of opioids and other 
substances in a chronic pain population has not received as much research attention, 
which is likely due, in part, to the complicated nature of defining substance misuse in 
the population. The difficulty in defining prescription opioid misuse in chronic pain 
populations is clearly illustrated in the varying estimates of the rates of misuse across 
studies as noted below. 
Prevalence of Opioid Misuse in Chronic Pain Populations 
There is inconsistent evidence of prescription drug abuse within the chronic pain 
population. Some studies report little to no abuse of prescription opioids (Cowan, 
Wilson-Barnett, Griffiths, & Allen, 2003; Dellemijn, 2001); however, other studies cite an 
increasing concern over misuse of prescriptions (Becker et al., 2008; Chabal, Erjavec, 
Jacobsen, Mariano, & Chaney, 1997). Hoffmann, Olofsson, Salen, and Wickstrom 
(1995) found that 23.4% of patients attending a chronic pain treatment center in 
Sweden met criteria for abuse and/or dependence of alcohol, opioids, or sedatives. In a 
review of the literature, Hojsted and Sjogren (2006) found that rates of prescription 
opioid misuse in chronic pain populations ranged from 0 to 50%, depending on the 
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definition of prescription abuse or misuse that was used and the method by which the 
information was collected. 
The difficulty in developing a clear definition of prescription abuse has been 
complicated by an ethical debate about the utility and risk of pain medications in chronic 
pain. There are likely few problems resulting from short-term use of opioid prescriptions; 
however, as mentioned above, many patients with chronic pain are prescribed a long-
term course of such medication. Daily use of prescription opioids leads to physiological 
changes such as a need for increased dosage (tolerance) and withdrawal symptoms. 
Sees and Clark (1993) suggested that a person who is prescribed opioids for pain could 
potentially meet for DSM-IIIR criteria of dependence without truly being dependent in a 
clinical sense. Additionally, Weissman and Haddox (1989) coined the term “pseudo-
addiction” referring to time-limited and reversible abuse symptoms that are suggestive 
of under-treated pain, rather than actual abuse or dependence. Another argument that 
was proposed to encourage the liberal treatment of chronic pain patients with opioid 
medications is the model of pain as an antagonist (a “block”) to the addictive properties 
of opioids (Kanner & Foley, 1981; Portenoy & Foley, 1986). Debates as to the 
meaningfulness of an abuse or dependence definition for prescription opioids have left 
some researchers and clinicians skeptical that abuse of prescription opioids in a chronic 
pain population even exists. Such skepticism could lead physicians and researchers to 
ignore serious warning signs of addictive behaviors.  
Alternatively, those on the opposite side of the debate over the meaningfulness 
of abuse and dependence on prescription opioids have attempted to demonstrate that 
all prescription opioids are dangerous. This belief could lead to under-treatment of 
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patients with chronic pain, thus leading to further suffering. This side of the argument 
has led to theoretical debates as to whether patients who present warning signs should 
be prescribed any opiate pain medication. For example, Cohen, Jasser, Herron, and 
Margolis (2002) published their own ethical dilemma as to whether a chronic pain 
patient with previous history of abuse of any substance should be prescribed pain 
medication at all.  
Despite the polarization of this debate within the literature, it appears that the 
need to relieve chronic pain patients of some suffering must be balanced with 
consideration as to whether opioid prescriptions warrant increased regulation for clients 
who present with risk factors for abuse. As stated by Erikson (2008), we need to 
consider the substantial impact of drug dependence which affects nearly 100 million 
people as opposed to the roughly 50 million with pain and also consider the cost to 
society of substance abuse which has been estimated at nearly 4 times the cost of 
“under-medicated pain (p. 1).” There are many theoretical publications on this debate, 
but it is essential to consider the working definition of prescription misuse and also the 
existing research studies that have begun to attempt to clarify the prevalence of 
substance abuse and the risks associated with development of substance abuse in a 
chronic pain population.  
Defining Prescription Misuse 
It is evident that there are many risk factors that remain to be explored to help in 
identifying chronic pain patients most at risk for prescription misuse and substance 
abuse. The ability to accurately identify misuse and appropriately assess it in both 
clinical and research settings continues to place limits on the utility of our findings. 
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Finding the most effective methods for eliciting accurate information from participants 
with chronic pain patients is a necessary step towards better identification of risk 
factors.   
There is inherent complication in identifying whether an individual is misusing a 
prescription opioid, because as described previously, many of the problematic 
symptoms of drug use, such as needing higher doses to get the same effect or 
withdrawal symptoms will likely arise even with appropriate use of pain medications. To 
address these complications, multiple scales have been developed to operationalize 
opioid prescription misuse and aid physicians in making the judgment as to whether 
their patients are misusing medications. Examination of a few of these scales provides a 
better picture of the conceptualization of prescription drug misuse that has been 
established thus far.  
One such measure is the Pain Medication Questionnaire (PMQ) developed by 
Adams et al. (2004). The PMQ is a list of aberrant, prescription drug related behaviors 
and was developed based upon previous clinical research and feedback from clinical 
personnel. The PMQ lists behaviors such as “I believe I would be better with a higher 
dosage of my pain medication” or “At times I drink alcohol to control my pain” and 
patients rate these items on a visual analogue scale. All of the items from this 
questionnaire are based on current risk factors such as use of other substances, 
personal concerns about their medication use, or need for increasing medication. 
Another measure is the Prescription Drug Use Questionnaire (PDUQ), which explores 
factors such as severity of pain, relationship with their treating physician, and current 
prescription misuse variables (Compton, Darakjian, & Miotto, 1998). The PDUQ differs 
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from the PMQ because of its explicit focus on pain and prescription factors rather than 
assumed risk factors of family substance abuse history and other substance use. A third 
established measure is the Screening for Addiction in Patients with Chronic pain and 
“Problematic” Substance Use (SOAPP; Butler et al., 2004; Butler, Fernandez, Benoit, 
Budman, & Jamison, 2008; Compton, Darakjian, & Miotto, 1998). The SOAPP was 
established by an expert panel which identified and rated assumed risk factors for 
prescription opioid abuse in a pain population. This scale includes questions regarding 
history of substance abuse and legal problems. In summary, the primary scales used 
currently to assess prescription opioid abuse in a chronic pain population focus either 
on current substance misuse behaviors or past history of any substance abuse to make 
predictions as to whether an individual patient is at risk. These established tools to 
predict and detect misuse of prescription opioids are limited in scope, focusing only on 
the narrow range of “risky” behaviors identified so far (e.g., illegal actions, misuse of 
other substances, and/or past history of substance abuse). 
Spurred by the lack of definition regarding misuse of prescription opioids, the 
American Pain Society (APS), the American Society of Addiction Medicine (ASAM), and 
the American Academy of Pain (AAP) developed a unified definition of misuse 
(American Pain Society, 2001).  As the American Pain Society reported, prior to this 
definition, each medical specialty had developed its own criteria for diagnosing 
prescription misuse. The definition provided by APS, ASAM and AAP is as follows: “a 
primary, chronic, neurobiological disease, with genetic, psychosocial, and 
environmental factors influencing its development and manifestations.” Unfortunately, 
this definition does not detail the thoughts, behaviors, and actions that should give 
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practitioners warning about an at-risk or abusing patient. Ballantyne and LaForge 
(2007), in a review of the literature, stated that the continued lack of a clear definition of 
prescription opioid misuse has caused substantial interference in the identification and 
treatment of chronic pain patients with an opioid addiction. Despite the efforts of APS, 
ASAM, and AAP, it appears that we are still lacking an operational, working definition 
from which to design our research questions and inform our treatment of chronic pain 
patients. As described above, our definition of prescription misuse has been developed 
in part by the working definitions used for research studies, and those studies will now 
be reviewed. 
Review of Prescription Opioid Misuse Research 
 The majority of the research on prescription opioid abuse in a chronic pain 
population stems from large national studies such as the National Survey on Drug Use 
and Health (Becker et al., 2008; Blanco et al., 2007; Compton & Volkow, 2006; Dowling, 
Store, & Chilcoat., 2006; Edlund et al., 2007; Eriksen et al., 2006; McCabe, Teter, Boyd, 
Knight, & Wechsler, 2005). One such study was conducted by Edlund et al. (2007), who 
analyzed surveys of nearly 9,300 people to compare substance use problems between 
individuals who have been regularly prescribed opioids and those who have not. The 
study showed that people who are regularly prescribed opioids for the treatment of pain 
had increased rates of opioid and other substance abuse problems compared to those 
who were not prescribed opioids regularly. The authors reported that the increased 
misuse of opioids and non-opioid substances in individuals prescribed opioids for pain 
were likely due in part to increased rates of anxiety and depressive disorders for 
individuals receiving prescription opioids.  
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Another epidemiological study was conducted by Eriksen et al. (2006) using data 
from the 2000 Danish Health and Morbidity Survey. Participants completed interviews 
and questionnaires regarding pain, quality of life, health care utilization and satisfaction, 
and medication and drug use. Eriksen and colleagues found that those patients 
prescribed long-term opioid treatments did not have improved pain relief, quality of life, 
or functional ability as compared to other pain patients not receiving medication. This 
led the authors to question the utility of broad usage of pain medication for all chronic 
pain patients and suggest more selective use. The epidemiological studies reviewed 
here provide preliminary concern over the occurrence of prescription misuse in a 
chronic pain population, but the large samples needed for these studies inherently 
limited the number of predictive factors that could be examined.   
 The next set of research studies on chronic pain and substance use are point 
prevalence studies of prescription misuse and other substance abuse in participants 
recruited from chronic pain clinics (Chabal et al., 1997; Fleming, Balousek, Klessig, 
Mundt, & Brown, 2007; Hoffman et al., 1995; Morasco & Dobscha, 2008; Reid et al., 
2002). These studies were focused on a smaller participant population, thus allowing 
exploration of additional concurrent and predictive factors suggestive of prescription 
misuse. Unfortunately, the factors explored in these studies were also limited and 
included: age (Fleming et al., 2007; Morasco & Dobscha, 2008), psychiatric comorbidity 
(Chabal et al., 1997; Fleming et al., 2007; Morasco & Dobscha, 2008), substance abuse 
histories (Chabal et al., 1997; Morasco & Dobscha, 2008), and concurrent abuse of 
other substances (Fleming et al., 2007; Hoffman et al., 1995).  
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Fleming et al. (2007) assessed 801 patients receiving a daily opioid treatment 
regimen from a primary care physician. Medical record reviews and interviews were 
used to examine point prevalence (9.7% any substance, 3.8% opioid) of substance use 
disorders within this population and it was found that those who abused their medication 
were younger, had a higher rate of psychiatric comorbidity, and higher rate of use of 
illicit substances. The authors also found that opioid use disorders were four times more 
likely within a chronic pain population being treated with opioids than those in the 
general population. Chabal et al. (1997) found that 27.6% of their clinic population at a 
major VA met at least three of the prescription opioid abuse symptoms determined by 
the researchers, such as requesting additional prescriptions or increased dose. The 
researchers examined previous history of alcohol or drug abuse and psychiatric history 
and found no differences between those who misused opioids and those who did not. 
As mentioned above, the concurrent factors explored in the studies described in this 
section were limited, but these studies do provide a model for continued exploration of 
additional risk factors. Prospective studies allow researchers to determine whether the 
factors shown to be associated with substance abuse in chronic pain (psychiatric 
comorbidity, age, etc.) can actually predict substance abuse or if those factors are 
merely an associated consequence of the substance abuse.  
 There has been one prospective study of prescription opioid abuse in a chronic 
pain population conducted. Ives and colleagues (2006) assessed patients attending a 
chronic pain clinic over a one-year period, following urine drug screens and medical 
records of requests for additional opioids. They reported age, gender, other substance 
misuse, and previous legal involvement as significant predictors of prescription opioid 
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misuse, whereas race, socio-economic status, depression and pain were not different 
between those who misused their medications and those who did not. The findings from 
the point-prevalence studies and the prospective study by Ives et al. (2006) have 
yielded different findings. For example, although psychiatric comorbidity was associated 
with higher rates of prescription misuse in point prevalence studies, depression was not 
related to prescription misuse in the prospective study. Although these differing results 
may in part be due to the nature of the methods used (e.g., psychiatric comorbidity may 
be shown in point prevalence studies because it is a consequence of substance abuse), 
there is a critical need to fully review the existing literature to determine the risk factors 
most commonly observed.   
In a review of the literature by Turk et al. (2008), the authors call for better 
measurements of prescription opioid abuse and use of reliable predictive measures, 
stating that the only strong predictor established thus far is a personal history of using 
illicit drugs. In a commentary on “The Rational Approach to the Treatment of Chronic 
Pain,” Gourlay, Heit, and Almahrezi (2005) expressed the need for physicians to 
practice caution and carefully assess all patients for potential abuse, and suggested a 
focus on reported past and present prescription misuse behaviors (Gourlay et al., 2005). 
Although the sentiment of Gourlay et al. is clear, it seems as though we should be able 
to assess variables that actually predict misuse, prior to the occurrence of misuse.  
Review of the current state of the literature provided above shows the limited 
extent of predictive variables explored within the chronic pain population. It remains 
evident that opioid treatment for pain is a necessary treatment for relieving the suffering 
of many of those experiencing chronic pain; however, we need more predictive tools to 
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identify the groups most at risk for the suffering caused by substance abuse and 
addiction. The independent literatures on chronic pain and substance abuse have 
addressed substantially more factors than those factors considered in the joint literature 
(e.g., expectancies, coping, and emotional factors). It is likely that misuse of prescription 
medications or other illicit substance use share common risk variables, such as trauma 
history (Logan, Walker, Cole, & Leukefeld, 2002) or emotional regulation factors 
(Handelsman et al., 2000; Jensen, Thomsen, & Hojsted 2005; Pinard, Negrete, 
Annable, & Audet, 1996) and an exploration of these factors is also necessary.  
Although the need for further identification of risks of prescription misuse is 
apparent, two primary challenges remain. The first complication that must be addressed 
is what additional risk factors should be explored based upon the existing literatures on 
chronic pain and on substance abuse. The second complication that must be addressed 
is how to identify substance misuse (and particularly prescription misuse) within a 
chronic pain population.  
Risk Factors 
 Next, four major areas of literature as related to both chronic pain and risk of 
substance abuse will be explored: traditional factors, pain factors, cognitive/social 
factors, and emotional factors. Although there is much research addressing each of 
these areas within the chronic pain literature and substance abuse literature, there have 
been few studies that unify the factors to apply them to substance abuse risk within a 
chronic pain population. Relevant studies for each area will be explored below.  
 Traditional factors such as age, gender, history of substance abuse, and history 
of psychological treatment are all factors that are readily available to a physician 
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working within a chronic pain population. As noted above (Becker et al., 2008; Blanco et 
al., 2007; Compton et al., 2006; Dowling et al., 2006; Edlund et al., 2006; Erikson et al., 
2006; McCabe et al., 2005), these factors have been established as the primary 
variables in the exploration of prescription opioid misuse.  
 Age and gender are two variables often considered within substance abuse 
literature. Review of national surveys has found increasing rates of opioid abuse 
(Compton & Volkow, 2006) and higher rates of abuse within younger age groups 
(Dowling et al., 2006; Fleming et al., 2007; Riley & Hastie, 2008) for both medical and 
non-medical abuses of opioids. The National Survey on Drug Use and Health has 
reported the highest rates of prescription opioid use amongst adolescents and older 
adults (over the age of 60). Gender is another variable that is quickly assessed by 
physicians and researchers; however, exploration of its predictive value has been 
limited. Most studies have recorded and controlled for gender when exploring opioid 
abuse in chronic pain patients for women and men rather than exploring differences. 
One study that examined gender differences of substance abuse in chronic pain 
patients reported higher rates of abuse among men (Ives et al., 2006).  
The most common factor that is quickly examined by physicians prescribing 
opioid medications is a patient’s history of prior drug or alcohol abuse. Michna et al. 
(2004) reported that past history of alcohol or other substance abuse was one of the 
most important factors in determining whether a chronic pain patient is at risk of misuse 
of prescription opioids. Michna and colleagues conducted a study to assess who would 
abuse prescription opioids, and found those with past history of abuse were more likely 
to have aberrant behaviors such as lost or stolen prescriptions or other illicit drugs in 
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their urine screens. Additionally, reviews of the literature report personal history of 
substance abuse as the only strong predictor that has been reliably assessed and 
shown to predict prescription opioid misuse across multiple studies (Compton & Volkow, 
2006; Turk et al., 2008). Despite the common use of this prior drug history in 
determining whether a patient is at risk of abusing their current prescription, there have 
been a few exceptions to this finding. For example, Chabal et al. (1997), in their study of 
97 VA patients prescribed opioids for the treatment of chronic pain, found that prior 
history of substance abuse did not significantly differ between patients who abused their 
opioid prescription and those who did not abuse their prescriptions. Because of 
inconsistent evidence for the usefulness of prior history of substance abuse as a 
predictor, it is clear that we need to consider other additional factors. 
Family history of substance abuse is another common variable considered in the 
substance abuse literature; however, research on family history of substance abuse as 
a predictor of prescription drug abuse is more limited. Studies that have examined 
family history of substance abuse or dependence have found significantly increased risk 
of opioid misuse for those with the most extensive family histories (Butler, Budman, 
Fernandez & Jamison, 2004; Hojsted & Sjogren, 2007).  
History of mental health treatment and/or psychiatric diagnosis has been another 
area frequently explored in the literature. Michna et al. (2004) found that chronic pain 
patients with higher rates of depression and anxiety were significantly more likely than 
others to abuse prescription opioids. Multiple studies have found increased rates of 
psychological treatment histories in chronic pain patients who misuse their prescription 
opioids (Becker et al., 2008; Lake, 2008; McWilliams, Clara, Murphy, Cox, & Sareen, 
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2008; Potter, Shiffman, & Weiss, 2008; Wasan et al., 2007; Weitzner, Cockram, & 
Strickland, 2003).  
Pain factors. The next area of literature is pain within the context of substance 
abuse risk. There is limited research regarding pain as a risk factor for substance 
abuse, however, both pain severity and pain coping are factors that physicians are likely 
already assessing in their care of chronic pain patients. It makes practical sense that 
increased pain severity may lead to increased prescription use. Additionally, as 
described previously, the under-treatment of pain, can lead to abuse-type symptoms 
such as requests for increased doses or stronger medications, using more of one’s 
prescription than advised, and/or dissatisfaction with treatment without there being 
additional behavioral concerns of addiction or misuse (Weissman & Haddox, 1989). 
Thus, pain severity is a complicated but essential variable to explore when assessing 
risk factors in chronic pain patients. 
Equally important is one’s ability to cope with pain. One potential area of interest 
within the pain coping literature is “pain catastrophizing.” Pain catastrophizing is a belief 
in negative, future outcomes of pain experience, and thus often leads to attempts to 
avoid or escape pain (Gatchel, Peng, Peters, Fuchs, & Turk, 2007). In a 10-year follow-
up of patients in a chronic pain clinic, Jensen et al. (2005) found that patients who were 
prescribed long-term opioid medication treatment had decreased levels of quality of life, 
more symptoms of depression, and increased use of the coping strategies of 
“catastrophizing” and “hoping and praying.”  
Cognitive/social factors. The third category of literature that will be explored is 
the category of cognitive and social predictive variables. Few prescription opioid misuse 
21 
 
studies have utilized these variables; yet, they are among the most commonly explored 
risks within alcohol literature (Cooper, Russell, Skinner, Frone, & Mudar, 1992; Tan, 
Nyugen, Cardin, & Jensen, 2006). Brown, Christiansen, and Goldman (1987) defined 
expectancies in alcohol use through the following categories: that it leads to positive 
effects, that it brings pleasure, that it leads to sexual enhancement, that it enhances 
social abilities, that it leads to relaxation, and that it leads to aggression/strength. 
Scheiffer and colleagues (2005) conducted a study of medication belief in chronic pain 
patients using a scale the researchers created based upon patient interviews. The 
medication beliefs assessed were: belief the medication would relieve pain, become 
addicting, increase functioning, improve affect/feelings, and need for increased 
medication. Scheiffer et al. (2005) found that chronic pain patients who reported 
previous histories of substance abuse also reported higher levels of beliefs in the 
effectiveness of the opioid medications.  
Other well-supported and commonly explored variables in the broader substance 
abuse literature are neuroticism and behavioral undercontrol (i.e., low 
conscientiousness) in alcohol research (Grekin, Sher, & Wood, 2006; Sher, Bartholow, 
& Wood, 2000). The construct of extraversion has been shown to have the strongest 
relationship with illicit drug use (Agrawal, Jacobson, Prescott, & Kendler, 2004; Gorman 
& Derzon, 2002), but the link between extraversion and alcohol use disorders is weaker. 
neuroticism and behavioral undercontrol (or low conscientiousness). There are no 
published studies that have explored the relationship between neuroticism, behavioral 
undercontrol (low conscientiousness), or extraversion and prescription misuse or other 
substance use in a chronic pain population.  
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Social support has been explored extensively as it relates to substance abuse in 
adolescence. Research has found that low levels of perceived and actual social support 
in adolescence are related to an increased risk of substance abuse in adolescence and 
adulthood (Chaffin, Kelleher, & Hollenberg, 1996; Myers, Brown, & Mott, 1993; Rhodes 
& Jason, 1990; Wills & Cleary, 1996; Wills & Vaughn, 1989). Within adult populations, 
most social support research has examined its relationship to substance abuse 
treatment outcome. Individuals with increased levels of perceived and actual social 
support in adulthood are more likely to engage in and complete treatment programs, 
have increased help seeking behavior, and maintain their recovery through follow-up 
(Aase, Jason, & Robinson, 2008; Oetzel, Duran, Jiang, & Lucero, 2007; 
Panchanadeswaran, El-Bassel, Gilbert, Wu, & Chang, 2008). Thus, research on social 
support has shown that low levels of support predicts substance use onset in 
adolescence and lower chances of recovery from substance abuse and dependence in 
adulthood.  
Emotional factors. Emotional factors are the least explored predictive factor in 
the prescription opioid misuse literature. This final category of predictive factors is the 
most difficult to assess, but the research within the two independent fields has provided 
rich explanations to some of our most perplexing questions of human experience. The 
concept of “self-medication” within the substance abuse literature also provides reason 
for exploring emotional factors within the context of prescription medication misuse. The 
“self-medication” concept was created primarily through clinical observations of patients 
in treatment for substance abuse. Khantzian (1997) describes a person’s attempt at 
self-regulation of uncomfortable or painful experiences of affect, self-esteem, and 
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relationships. As the term suggests, in this model, substances are used to mask or 
avoid these uncomfortable or painful affective and/or relational experiences. 
Additionally, there is a large body of research in the alcohol literature that has examined 
the motive to use alcohol to manage stress and emotions (Cooper, Frone, Russell, & 
Mudar, 1995) that suggests that people who regulate their emotional experiences 
through the use of alcohol are more likely to develop abuse symptoms. There is some 
research to suggest that emotion regulation based motives to use nonmedical 
prescription drugs (e.g., nonprescribed sedatives, opioids, stimulants) are also 
associated with higher rates of abuse (McCabe, Boyd, & Teter, 2009). Despite the 
prevalence of this model within clinical practice, emotional regulation factors have been 
largely ignored within the literature on prescription misuse in chronic pain patients.  
Experience of stressful or traumatic events has been linked to both the presence 
and severity of chronic pain conditions (Green, Flowe-Valencia, Rosenblum, & Tait, 
2001; Finestone et al., 2000; Sachs-Ericsson, Kendall-Tackett, & Hernandez, 2007) and 
substance abuse and dependence (Logan et al., 2002; Wilsnack, Vogeltanz, Klassen, & 
Harris, 1997). Finestone and colleagues (2000) found that childhood sexual abuse is 
positively related to chronic pain. Research has also suggested that individuals with 
past traumas are more likely to abuse substances. Wilsnack and colleagues (1997) 
used a national survey that assessed childhood sexual abuse and use of substances 
and found that those women who experienced childhood abuse were significantly more 
likely to abuse alcohol and other illicit substances. In a review of the literature on 
substance abuse and trauma histories, Logan and colleagues (2002) reported a high 
rate of co-occurrence of trauma and substance abuse and dependence in women. The 
24 
 
researchers developed a complex model suggesting that the relationship between 
trauma and substance abuse in women can be explained by trauma and coping factors, 
lifestyle factors, sociological factors, and contextual factors. Uniting the chronic pain and 
substance literature, Green and colleagues (2001) studied women presenting for 
chronic pain management and found that nearly half had experienced trauma, and 
those with long-term abuse had higher incidence of substance abuse.  
A person’s general approach to coping with emotions can have a substantial 
impact on their psychological and physical functioning. In general, emotionally focused 
coping has been shown to lead to a variety of deleterious outcomes. However, one 
specific type of emotionally focused coping, emotional approach coping, has been 
shown to actually predict better outcomes in a variety of studies (Austenfeld  & Stanton, 
2004; Smith, Lumley, & Longo, 2002). Previous research has also shown that within a 
chronic pain population, emotional approach coping specifically may lead to decreased 
pain and depression (Smith et al., 2002). Emotional approach coping is the tendency of 
a person to understand and process or use emotions throughout one’s daily life. 
Emotional approach coping is one’s general approach to dealing with emotional 
information in their life. Because we know that emotional approach coping leads to 
decreased pain and depression (Smith et al., 2002), both of which we have reason to 
predict relate to prescription misuse and substance abuse, emotional approach coping 
is an important variable to explore.  
Alexithymia is a widely researched emotional regulation concept which is defined 
as difficulty indentifying and describing feelings, externally oriented thought and limited 
imaginal ability (Nemiah, Freyberger, & Sifneos, 1976; Taylor, Bagby, & Parker, 1997). 
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Although alexithymia was originally studied in people with psychosomatic disorders, 
research shows it to be a risk factor for many problems, including chronic pain and 
substance dependence (Taylor et al., 1997). Recent research has begun to connect the 
experience and maintenance of chronic pain with alexithymia (Ak, Sayer, & Yontem, 
2004; Burba et al., 2006; Celikel & Saatcioglu, 2006; Lumley, Neely, & Burger, 2007). 
There have been no published studies relating alexithymia to prescription drug misuse 
in chronic pain patients; however, there has been some research on the relationship of 
alexithymia to other drugs of abuse (Handelsman et al., 2000; Pinard et al., 1996). 
Pinard and colleagues (1996) examined the alexithymia scores on the Toronto 
Alexithymia Scale-20 (TAS-20) at baseline in a drug treatment center and found that 
patients attending drug treatment had significantly higher scores on the TAS-20 than 
non-patients. The researchers also repeated the TAS-20 at completion of treatment and 
found no significant differences from baseline to treatment completion, suggesting that 
alexithymia is relatively stable within this group and is likely not a direct effect of active 
substance use. 
Further, emotional regulation techniques have also been linked to chronic pain 
and coping with pain (DeGenova, Patton, Jurich, & Macermid, 1994; Leitenberg, 
Greenwald, & Cado, 1992). The two primary regulation techniques that have been 
explored are avoidant and emotion focused coping which may lead to increased pain 
symptoms, emotional distress, and general negative outcomes. Although emotional 
regulation techniques have been suggested as a factor in substance abuse through the 
“self-medication” model, there have been no published studies exploring avoidant and 
emotion focused coping directly. Theoretically, within the “self-medication” model, it 
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would seem as though individuals who engage in avoidant coping techniques may be 
more likely to engage in substance abuse behaviors as an escape process, but there is 
no current literature to support this claim. 
In addition to our lack of an operational definition of prescription misuse and 
mixed results regarding predictive factors of prescription misuse and other substance 
use in a chronic pain population, our understanding of this serious problem is also 
limited by our ability to collect accurate information in both research and clinical 
settings. Gathering accurate self-report of a stigmatizing behavior such as prescription 
misuse or other substance abuse can be challenging. The researcher or clinician must 
develop methods to overcome the many motivations that prevent people from sharing 
these behaviors (e.g., being looked down upon, decreasing their chances of receiving 
prescription medications,   being unaware that their behavior could be problematic).  
Disclosure of Stigmatized Behaviors 
 Disclosure of stigmatized behaviors in research, and specifically drug use, 
requires a balance of the researcher’s need for reliable, and consistent information with 
a participant’s comfort in sharing based on beliefs of confidentiality, trust in the 
researcher, and clear understanding of the questions being asked. Under-reporting in 
studies of drug use has been a long documented problem (Andrews, Kendler, Gillespie, 
& Neale, 2007; Booth-Kewley, Larson, & Miyoshi, 2007; Fendrich, Wislar, & Johnson, 
2003).  Of particular interest in understanding the accuracy of self-reported of misuse of 
prescription opioid medications, it has been found that people who face potential legal 
or social consequences from reporting their substance use provide less accurate 
reports (Golub, Liberty, & Johnson, 2005; Grekin et al. 2010). As reporting misuse 
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symptoms related to prescription opioids could potentially lead to the discontinuation of 
treatment at many clinics, the motivation to conceal use is likely high. The unreliability of 
self-report has led many researchers to examine physiological measures of substance 
use such as urine drug screens or hair tests; however, such tests can not assess the 
behavioral attributes of abuse or dependence symptoms (Schuckman, Hazelett, Powell, 
& Steer, 2008). There is a need to continue improving our methods of increasing self-
report of both misuse of prescription medications and use of illicit drugs and alcohol, as 
the most serious consequences of use are behaviors and desires that can only be 
reported through the participant.  
Disclosure in health care settings involves further barriers to accurate self-report 
of symptoms and behaviors because of the potential impact it may have on the doctor-
patient relationship. Studies have examined the role of explicit discussion over 
confidentiality of medical information. Parrot, Duncan, and Duggan (2000) explored the 
literature on patient “impression management” and the impact this has on a caregiver’s 
ability to obtain sensitive or stigmatizing behaviors. The authors concluded that it is a 
delicate process that requires attention to “organizational, cultural, personal, and 
interactional strategies.” A patient may have concerns about requesting additional 
medication even when needed, because of fears of appearing as though they are 
misusing medications. Patients may also want to appear healthier so that a physician 
will reduce restrictions, continue current medical care, and in some instances avoid 
concerns about prescription use.  
 Schuckman et al. (2008) conducted a 6-year record review of patients who came 
to the emergency department seeking pain medications. The researchers examined the 
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patients’ self-reported drug use and compared it to a drug screen that same day. In 
analyses conducted to characterize the difference between people whose self-report 
matched the drug screen (68%) and those whose self-report did not match the drug 
screen (32%), it was found that individuals with a history of chronic pain or drug abuse 
were significantly more likely to have inaccurate self-reports. Reinhard et al. (2007) 
found that individuals who were more inaccurate with their self-reported stimulant use 
were also less likely to report symptoms of psychopathology. Taken together, these two 
studies (Reinhard et al., 2007; Schuckman et al., 2008) provide evidence that self-
reported use of substances is often inaccurate. These two studies also show that in 
chronic pain populations there may be additional reasons for concern about the 
accuracy of reports and that individuals who are more likely to conceal substance use 
may also be more likely to conceal other psychological symptoms. In clinical settings, 
biological drug tests may not always be convenient or cost-effective and the common 
inaccuracy of self-report provides further reason to improve our methods for increasing 
the accuracy of self-report. 
Another topic that is often under-reported is the experience of trauma. Research 
has shown that disclosure of traumatic experiences can be increased by a participant’s 
perceived sensitivity of the researcher and the belief in confidentiality of the disclosed 
information (Denov, 2003; Leibowitz, Jeffreys, Copeland, & Noel, 2008; Mueller, 
Moergli, & Maercker, 2008).  Because the experience of traumatic or stressful 
experiences can have such a significant impact on one’s physical and mental health, in 
addition to quality of life, it is essential that we continue to develop means to best 
identify individuals with trauma histories so that treatment and prevention efforts can be 
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targeted towards them.  Rosenbaum and Langhinrichsen-Rohling (2006) reviewed the 
literature on disclosure of trauma and found the two main factors to consider in 
participant disclosure are “willingness to disclose” and “accuracy of disclosure,” both of 
which should be considered in any research study. Additionally, the authors call for all 
researchers assessing sensitive or stigmatizing information to work to improve research 
methodologies to improve internal and external validity of our studies.   
There has been recent interest on how to improve self-report of stigmatized 
behaviors in research studies and in medical offices. Much of the research has focused 
on the evaluation of new technologies to improve self-report (Booth-Kewley et al., 2007; 
Joinson, Woodley, & Reips, 2007). Computerized measures have been created for 
assessing substance abuse, risky sexual behaviors, and HIV risk behaviors. Most 
research has shown increased rates of disclosure of stigmatized behavior using 
methods that provide the participant the most distance from the researcher (e.g., 
telephone screens, computerized measures). Additionally, some research has 
suggested that spoken disclosure in the presence of another individual may actually 
inhibit emotional expression (Newman et al., 2002), possibly making participants more 
self-conscious of what they are disclosing and making them feel as though they may be 
judged for their disclosure.  
Interestingly, with all of the attempts to improve participant reports through 
technology, there have been limited attempts at improving the interviewer’s 
methodology. The therapy literature suggests that techniques such as meta-
communication about relationship factors and about comfort sharing can improve 
alliance and ultimately increase disclosures. Recent research within the emotional 
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disclosure literature suggests that an active and engaging facilitator may lead to 
increased degrees of engagement and disclosure. However, the ability of these 
techniques to improve self-report of substance abuse and traumatic or stressful 
experiences in research settings has not been explored. Next, therapy and emotional 
disclosure literatures will be explored.  
Social versus non-social sharing and characteristics of the participant-facilitator 
relationship may both have an effect on the content quality of the disclosure session. 
Social versus non-social sharing has been examined by comparing private writing tasks 
to socially disclosing to a researcher. Newman et al. (2002) compared the degree of 
disclosure of potentially stigmatizing events among individuals who had presented to a 
syringe exchange program. In this study one group was asked to type their disclosures 
on a computer program, whereas another group was asked to disclose in a face-to-face 
interview. It was found that individuals were most likely to disclose more information 
privately than face-to-face. 
In addition to characteristics of the sharing person and his/her experience, 
facilitators can vary in their responses.  Psychotherapy theory and practice suggests a 
continuum of therapist responses.  On the one hand, therapists can be either supportive 
and non-directive, by using techniques such as active listening, reflection, and following.  
Alternatively, they can be more active, working to facilitate disclosure and processing by 
questioning, exploring, and encouraging experiential exercises. Research by 
Laurenceau, Barrett, and Pietromonaco (1998) suggests that in interpersonal 
disclosures, the responsiveness of the therapist may increase participant’s feelings of 
intimacy in the relationship and thus lead to more disclosure. Responsiveness of a 
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therapist may involve both verbal (e.g., reflections, guiding questions, etc.) and 
nonverbal (e.g., body posture, head nods, facial expression) signs displayed by the 
listener, showing interest and concern to the discloser. Based on this study, it is unclear 
whether different methods of responsiveness by the therapist may provide the most 
appropriate interaction for the highest degree of disclosure and emotionality.  
A recent study by Sander et al. (2008) examined four forms of disclosure (i.e., 
writing privately, talking privately, talking with a “passive” facilitator, and talking with an 
“active” facilitator) to explore which method leads to the most disclosure in a brief, 30-
minute session. In all four conditions, the participants were provided with the same set 
of instructions regarding what they should disclose during the session. The “passive” 
facilitator was supportive and engaged, but did not encourage further disclosure through 
questioning and did not meta-communicate about the session. The “active” facilitator 
began the session by meta-communicating about the concerns the participant may have 
about disclosing, encouraged further exploration of missing emotions or facts about 
their experience, and normalized thoughts and feelings about the experience. The 
findings suggest that people can be “pushed” further by an “active” facilitator in both 
emotional engagement and cognitive processing, but may actually be inhibited by a 
“passive” facilitator. Individuals who have experienced stressful or traumatic 
experiences seem very capable of being pushed for more disclosure and more 
emotional involvement in session.  
Most self-report data gathered in previous studies of the accuracy of self-report 
have typically used the “passive” facilitator method. The findings of Sander et al. (2008) 
suggest that the “passive” model may lead to inhibition and discomfort in the method. 
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The typical use of a “passive” facilitator in clinical interviews may explain why research 
has suggested that interpersonal methods have not worked as well as computerized 
methods for gathering information about stigmatized behaviors. The model of “active 
facilitation” described in Sander et al. (2008) may also lead to increased disclosure of 
stigmatized behaviors such as substance abuse; however, this has not been explored in 
the literature. As described previously, medical settings inherently create additional 
barriers to accurate disclosure of prescription misuse and substance abuse because of 
the potential impact on their care. The process of meta-communication and 
normalization of the worries about sharing drug use may help ease some of those 
concerns and increase accuracy of self-report.  
Goals and Hypotheses 
The current study sought to develop a model of predictive factors in which the 
traditional factors, pain factors, social/cognitive factors, and emotional factors each 
explain unique portions of variance in the misuse of prescription medication, alcohol and 
other substances in a chronic pain population. As most of the previous research has 
been conducted using convenience samples and record reviews, there have not been 
studies that bring together each of these key variables into a single population of 
patients. Patients attending a local chronic pain clinic were assessed for each of these 
key variables and for symptoms of prescription medication misuse and use of alcohol 
and illicit substances at a single evaluation session. In addition, to bring together all of 
the previously explored key variables in the literature, this study also sought to explore 
emotional factors as they relate to prescription opioid misuse in chronic pain patients. 
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The emotional factors of alexithymia, emotional approach coping, and the experience of 
trauma were explored.  
 This study also tested different methods of data collection that may increase the 
self-reported sensitive information of prescription misuse, substance abuse or 
dependence, and experience of stressful or traumatic experiences. Much of the 
previous research regarding assessment of stigmatized or sensitive information has 
explored computerized methods to increase distance and beliefs of confidentiality 
between the researcher and the participant. In the current study, a novel interviewer 
procedure was designed to facilitate discussions of confidentiality and meta-
communication about the interviewer-participant relationship and the sensitivity of the 
information the participant is being asked to report. Three methods of data collection for 
substance use and trauma history were tested: enhanced interviewer, standard 
interviewer, and questionnaires. 
 Overall, this study had three goals: a) develop a model of predictive factors for 
chronic pain patients, bringing together the variety of factors that have been explored 
independently in previous studies; b) add emotional factors to the predictive model to 
assess whether these factors can explain unique variance beyond the traditionally 
explored variables: and c) develop and experimentally test methods by which the most 
sensitive information is disclosed by participants.  
Concurrent Predictors of Prescription Drug Abuse  
Aim 1. Determine which demographic, pain-related, cognitive/social, and 
stress/emotional factors predict prescription misuse and abuse and dependence 
symptoms for prescription opioids among patients in treatment for chronic pain. 
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Hypothesis 1. It was predicted that higher levels of prescription misuse and 
symptoms of abuse and dependence would be associated with younger age, 
lower social support, previous history of psychiatric diagnosis, high 
catastrophizing of pain, high expectations for the effects of the prescription, high 
extraversion, alexithymia, high levels of emotional ambivalence, and low levels of 
emotional approach coping.  
Aim 1a. Test whether factors related to stress and emotion regulation (low 
emotional awareness and expression, high experience and impact of lifetime 
trauma) predicted prescription misuse beyond more routinely assessed and 
established factors. 
Hypothesis 1a. It was hypothesized that a model building in emotional variables 
can increase the predictive ability of common medical belief of who might be at 
greater risk of showing abuse characteristics with prescription opioids and with 
the use of other substances.  Specifically, it was predicted that higher levels of 
alexithymia, lower levels of emotional approach coping, and more experience of 
trauma and impact of trauma will explain additional variance predicting 
concurrent prescription misuse and abuse and dependence symptoms for 
prescription opioids, as measured by the PDUQ, beyond traditional, pain, and 
cognitive/social factors.  
Aim 2. Determine which demographic, pain-related, cognitive/social, and 
stress/emotional factors predicted use of alcohol and illicit substances among patients 
in treatment for chronic pain. 
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Hypothesis 2. It was predicted that higher levels of alcohol and illicit substance 
use will be associated with younger age, lower social support, previous history of 
psychiatric diagnoses, high catastrophizing of pain, high expectations for the 
effects of the prescription, high extraversion, alexithymia, and low levels of 
emotional approach coping.  
Aim 2a. Test whether knowledge of factors related to stress and emotion 
regulation (low emotional awareness and expression, high experience and 
impact of lifetime trauma) predicted alcohol and illicit substance beyond more 
routinely assessed and established factors. 
Hypothesis 2a. It was predicted that higher current levels of alcohol and other 
illicit drug use would be associated with higher levels of alexithymia, lower levels 
of emotional approach coping, and more experience of trauma and impact of 
trauma, beyond traditional, pain, and cognitive/social factors.  
Methods of Disclosure of Stigmatized Information 
Aim 3. Determine whether variations in assessment methods lead to differing 
amounts of disclosure of aberrant use of prescription drugs, use of alcohol and other 
drugs, and trauma history. 
Hypothesis 3. It was predicted that higher reported misuse of prescription 
medication, use of alcohol and illicit drugs, and experience of stressful events or 
traumas would occur in the following order: enhanced interview (highest), written, 
standard interview (lowest). 
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CHAPTER 2 
 
METHODS 
 
Participants 
 Participants were 100 patients with chronic pain who were receiving treatment 
through a local pain management clinic. All participants reported chronic pain for at 
least 3 months prior to study participation and were prescribed a self-administered 
opioid at the time of assessment. Participants were excluded from the study if they 
reported non-literacy in English and/or they were not actively receiving treatment 
through the pain management clinic at which all recruitment occurred. Participants were 
recruited from August 2009 through November 2010. 
A total of 103 participants met criteria and came to the laboratory or the pain 
clinic for their study visit. Of the 103 participants who started the study, 100 (97%) 
completed the full session and were included in analyses. An additional 23 people met 
study criteria and scheduled a study visit, but did not attend their session. 
Approximately 20 people who called the laboratory stating that they were interested in 
participating did not meet study criteria, and the primary reasons were that they were 
not attending the pain management clinic through which the study recruited or they 
were not currently prescribed an opioid. In the final sample of 100 participants, 47% 
were male and 53% were female, and the sample had an average age of 47.57 years 
(SD = 11.57). The sample was predominantly African-American (81.0%), with other 
participants identifying as Caucasian (11.0%), or other (3.0%), and a small portion 
chose not to disclose their ethnicity (5%). 
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Procedure 
Participants were recruited through pamphlets provided in the clinic waiting room 
of the pain management clinic (see Appendix A). The pamphlets included a brief 
description of the study and provided a phone number at which study personnel could 
be reached to provide further information regarding the study. Additionally, study 
personnel approached participants in the waiting room of the pain clinic and provided 
information to interested patients. The study personnel recorded phone numbers of 
patients who requested to be contacted for an appointment. More than half of the 
participants approached reported interest in receiving more information and possibly 
participating in the study. Of those participants who did not report interest in 
participating, the most common reasons were: no interest in being in any research 
study, limited time or transportation, and knowing that they did not meet criteria (e.g., 
first session at the clinic).  
 All potential participants were contacted via phone and provided more 
information about the study and protocol (See Appendix B). Patients were then 
scheduled for a study visit at a time convenient to them either at the laboratory or the 
pain management clinic. Participants were called the day prior to their scheduled study 
visit to remind them of the date and time of their session.  
 Study visits were conducted in private rooms to ensure privacy of the participant, 
and the physicians were not allowed access to an individual participant’s data. Upon 
arrival to the study visit, the participant was greeted by the researcher and provided the 
information sheet in lieu of consent approved by the Wayne State University Human 
Investigation Committee (Appendix C). The researcher reviewed the information sheet 
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with the participant and answered any questions the participant had at that time. Upon 
review of the study with the Human Investigation Committee, it was determined  that if 
participants reported misuse of their medications and the researchers were aware of the 
patients’ names, we would be required to inform their clinicians at the pain management 
clinic of their misuse. Thus, the information sheet was provided as an alternative to a 
signed informed consent form to maintain anonymity of participants because it was 
believed that it would interfere with the study if disclosure of medication misuse and/or 
drug use would lead to potential consequences such as discharge from their pain 
management program. After the consent process, the participants began the non-
randomized portion of the study, completing paper-and-pencil questionnaires.  
The first portion of the evaluation was identical for all participants. All participants 
completed multiple questionnaires in paper-and-pencil format regarding demographic 
information, alexithymia, pain disability, mood, and emotional expression. Participants 
were then randomized into one of three groups. The researcher opened a sheet of 
paper which was stapled to the back of the participant folder to reveal the participant’s 
group (group assignments are described below in “Experimental Groups”). Participants 
then engaged in one of the three, randomized, information-gathering formats for the 
remainder of the evaluation, which included information on trauma, prescription misuse, 
and alcohol and other drug use.  The final measure was written, and private for all 
groups, which was ratings of their comfort with the method of assessment that they 
engaged in and the degree to which they were able to be open about their substance 
use and stressful life events. The entire study session lasted approximately 1.5 to 2 
hours. At the completion of their visit, participants were compensated $30 for their 
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participation in the study and provided a list of local mental health treatment facilities, 
substance abuse treatment facilities, and emergency hotlines. 
 Experimental groups. After completing the informed consent process, 
participants first completed the non-randomized paper and pencil questionnaires 
privately. Participants were then randomized to one of the three groups to complete the 
measures of potentially stigmatizing information (i.e., substance use, medication 
misuse, and experience of trauma). The three groups were as follows: written, standard 
interview, and enhanced interview. Participants were randomized into one of the three 
conditions in blocks of 6 (resulting in equal numbers of patients in each group after 
multiples of six), using a random number sequence generated by a computer 
(randomization.com). The randomization list was stratified by patient gender and by 
researcher/interviewer. After the initial paper and pencil questionnaires, two of the three 
groups met with an interviewer, who was a graduate student in clinical psychology, 
while the other group was written and completed in private. The randomized portion of 
the evaluation lasted approximately 30 minutes. At the completion of the randomized 
portion of the session, the participant then completed the final session evaluation.  
Written evaluation. Participants assigned to the written evaluation completed all 
portions of the study on paper and pencil questionnaires. After completing the predictor 
measures, the researcher returned to the room and collected those measures. The 
researcher then provided the participant the trauma and substance use forms, briefly 
explaining the scales used on each, and then allowed the participant to complete the 
forms in private. These participants completed assessments of traumatic and stressful 
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experiences, evaluation of current and past use of alcohol and illicit substances, and 
prescription misuse in written format.  
 Standard interview evaluation. These participants spoke to a standard 
interviewer.  The questions were identical to those in the written format, but were read 
aloud to the participant by an interviewer. Participants randomized to this group 
completed assessments of traumatic and stressful experiences, evaluation of current 
and past use of alcohol and illicit substances, and prescription misuse portion of the 
evaluation with the interviewer. The interviewer was attentive, empathic, but passive, 
simply asking the structured questions and recording the participant’s responses to 
each of the listed questions. The interviewer was able to respond to any concerns the 
participant may have had about specific questions, identical to the way they would have 
responded to concerns of participants in the written evaluation group. In this condition 
the interviewer was attentive to the participant but did not provide any prompts to 
explore further the emotions or facts, nor did the researcher meta-communicate about 
the session. The interviewer guidelines for this condition are in Appendix D. The 
structured interview questions were identical to those used in the Enhanced Interview 
group (described next).  
Enhanced interview evaluation. The participants assigned to this group spoke 
to an enhanced interviewer for the assessments of traumatic and stressful experiences, 
evaluation of current and past use of alcohol and illicit substances, and prescription 
misuse. The questions for this group were again identical to the two previous groups. 
However, in this group the interviewer was an active part of the process of gathering 
information. The interviewer began this portion of the session with meta-communication 
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about confidentiality of the interview and normalizing the occurrence of prescription 
misuse and substance use and concerns that they might have about sharing personal 
information with someone that they do not know. In this condition, the interviewer also 
engaged in follow-up questions when information seemed contradictory or unclear 
during the interview. The interviewer also encouraged continued disclosure if the 
participant seemed hesitant or nervous about providing answers to specific questions. 
The interviewer tried to identify missing content in the participant’s responses and 
encouraged further exploration of these areas, while also returning to meta-
communication about the session and/or interviewer-participant relationship when it 
seemed necessary. At the beginning of this portion of the session and at specified 
points during the questioning, the interviewer followed a script designed to normalize 
the experience of these potentially stigmatizing behaviors and validate their concerns 
about sharing these behaviors. The interviewer expressed understanding of the concern 
the participant may have in sharing prescription misuse, substance abuse, or trauma, 
while also encouraging them to provide honest responses. The enhanced interviewer 
guidelines are in Appendix D.  After completing either of the interviewer conditions, as a 
manipulation check, participants answered a brief questionnaire regarding the degree to 
which the interviewer encouraged them to share. 
Measures 
 As stated previously, the purpose of this study was two-fold. The first purpose of 
this study was the development of a model using four main areas of interest for 
predicting abuse of substances, including prescription drugs. The four main areas were 
traditional information (e.g., sex, age, family history of abuse, psychiatric symptoms), 
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pain factors (e.g., severity, pain coping), social/cognitive factors (e.g., social support, 
expectancies, personality), and emotional factors (e.g., trauma, alexithymia, emotional 
coping styles). The scales used to assess each of these areas are described below. 
The final section of measures is the outcome measure of current misuse of prescription 
drugs and other substances. Measures assessing the participants’ reactions to each of 
these three groups will also be described below.  
Traditional Information 
The traditional information gathered was sex, substance abuse history of any 
drug, parental substance abuse, length of time in treatment, and mood/anxiety 
symptoms. This information was collected through a paper survey developed by the 
researcher. These are traditional pieces of information that can be gathered on a 
doctor’s visit which may or may not lead to a physician’s perception that the individual is 
at risk for abusing his or her prescription pain medication.  
Psychiatric symptoms. Psychiatric symptoms were assessed using the Brief 
Symptom Inventory (BSI; Deragotis, 1975). The BSI consists of 53 items, each of which 
is rated on a 0 (not at all) to 5 (extremely) scale corresponding to how much they have 
been distressed about each symptom over the past 7 days. There are 9 subscales and 
3 global indices which assess distress over symptoms and experience of symptoms 
broadly: Global Severity Index (GSI), Positive Symptom Distress Index, and Positive 
Symptom Total. Other dimensions that can be analyzed are as follows: Somatization, 
Obsession-Compulsion, Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic 
anxiety, Paranoid ideation and Psychoticism. The GSI is the most broadly used 
composite score and has good test-retest reliability (Deragotis, 1993) and validity 
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(Conoley & Kramer, 1989; Derogatis, Rickels, & Rock, 1976). Only the GSI was 
analyzed for the purpose of the current study. The GSI was highly reliable for this 
sample (α = .98). 
Pain Information 
The pain information that was gathered was used to assess both pain severity 
and pain coping.  
Pain severity. Pain severity was assessed by the Brief Pain Inventory (BPI) 
which was developed by the Pain Research Group (Daut, Cleeland, & Flanery, 1983). It 
includes two scales: pain severity and pain interference. Only the pain severity total was 
used for analyses. All items of the BPI are rated on a 0 to 10 rating scale, and ask 
responders to rate how their pain is at that moment in time, and the worst, least, and 
average over the past week. The BPI is used widely to assess functioning across 
various pain problems. The BPI had an acceptably high internal reliability in this sample 
(α = .83). 
Pain coping. Pain coping was assessed by two measures. The first pain coping 
measure was the Pain Catastrophizing Scale (PCS; Sulllivan, Bishop, & Pivik, 1995). 
The PCS is a 12-item scale used to assess rumination, magnification, and helplessness 
from pain, with alphas of .87, .60 and .79 respectively (Sullivan, et al., 1995). Sullivan et 
al. (1995) found that people scoring high on this scale had higher levels of emotional 
distress and increased thoughts about and intensity ratings of pain. Sullivan et al. 
(1995) also found that the PCS significantly correlates with pain intensity, beyond 
measures of negative affectivity and emotional distress. The full scale of the PCS was 
used in this study, and it had high internal reliability (α = .93). 
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The second pain coping measure used was the Pain Anxiety Symptom Scale 
(PASS), which was originally developed by McCracken, Zayfert, and Gross (1991). The 
PASS has been shown to have good internal consistency and validity (McCracken, 
Zayfert, & Gross, 1992). The internal consistency was found to be high in this sample 
(α = .94). The Pain Anxiety Symptom Scale-Revised (PASS-R; McWilliams & 
Asmundson, 1998) was used in this study. The PASS-R consists of the following 
subscales: Interference, Approach Behaviors, Catastrophic Thoughts, Monitoring and 
Prevention, and Physiological Arousal. The PASS-R Total score (PASS-TOT) was 
analyzed for this study.  
Cognitive/Social Factors 
For this domain, social support, expectancies, and personality were assessed.  
Social support. Social support was assessed using the Social Provisions Scale 
(SPS; Cutrona & Russell, 1987). The SPS consists of 12 items and can be divided into 
the following six subscales (four items each): Attachment, Social Integration, 
Reassurance of Worth, Reliable Alliance, Guidance, and Opportunity for Nurturance. 
The SPS can also produce a Global Social Support score. The SPS has been used 
widely as a measure of support in stressful or emotionally challenging events such as 
dealing with an illness, taking care of sick relatives, and even for stressful employment 
experiences. The Global Social Support score was used for the purpose of our 
analyses, and it was found to have an acceptably high internal reliability for a research 
measure (α = .74). 
Beliefs. Pain medication beliefs were assessed using an opioid medication 
beliefs scale developed by Schieffer et al. (2005). As the scale was designed for 
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descriptive purposes, one item from the scale was chosen to represent pain medication 
beliefs. The item used was a rating of how much medication the participant felt they 
needed compared to other pain patients: none at all, a little, about the same, a little 
more, or much more.  
Personality. Personality factors were assessed using the Ten Item Personality 
Inventory (TIPI; Gosling, Rentfrow, & Swann, 2003) which assesses Openness, 
Conscientiousness, Agreeableness, Emotional Stability (reverse of Neuroticism), and 
Extraversion. As the name suggests, the TIPI consists of 10-items rated on a scale of 
1(strongly disagree) to 7(strongly agree), regarding how much they believe that the 
statement applies to him or her. Each subscale consists of two items.  
Emotional Factors 
Emotional factors that were examined for this study were stress symptoms and 
emotional regulation measures. 
Stress symptoms. The Impact of Events Scale was originally developed by 
Horowitz, Wilner, and Alvarez (1979) to assess subjective distress as a result of 
traumatic experiences. The Impact of Events Scale includes subscales for Avoidance, 
Intrusions, and a Total score. The Impact of Events Scale-Revised (IES-R; Weiss & 
Marmar, 1996) was used for the purpose of this study which includes the additional 
scale of Hyperarousal. The IES-R contains 22-items which are based upon the DSM-IV 
symptoms of PTSD. Each item is rated on a 0 (not at all) to 5 (extremely) scale 
regarding how bothered they have been by each symptom over the past 7 days. 
Because the participants who were recruited into the study had not all experienced a 
traumatic event as defined by the DSM-IV, the introduction to this scale was modified to 
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include a broader conception of stressful experiences. The IES Total Score was highly 
reliable in this sample (α = .95). 
Alexithymia. The Toronto Alexithymia Scale-20 (TAS-20; Bagby, Parker, & 
Taylor, 1994) assesses global alexithymia, and three additional facets of alexithymia: 
difficulty identifying feelings, difficulty describing feelings, and externally oriented 
thinking.  The scale has good reliability and is the most extensively validated measure 
of alexithymia (Bagby, Taylor, & Parker, 1994). Because the three subscales of the 
TAS-20 appear to have differential validity and tap different aspects of emotional 
regulation, the subscales were analyzed as well as the total score (α = .80) for this 
study.  
Emotional ambivalence. To assess the experience of desiring to express 
emotions and conscious inhibition of expression, the Ambivalence Over Emotional 
Expression Questionnaire (AEQ; King & Emmons, 1990) was used. The AEQ has high 
reliability and also predicts negative mood and physical symptoms better than measures 
assessing the frequency of expressing emotion (King & Emmons, 1990).  This study 
used a 14-item short version of the scale, which had high internal reliability for the AEQ 
total score (AEQ-TOT; α = .90). 
Tendency to seek emotional support. The 8-item Emotional Approach Coping 
scale (EAC; Stanton, Danoff-Burg, Cameron, & Ellis, 1994) assesses emotion-oriented 
coping. The EAC contains two subscales: emotional processing (seeking to understand 
and identify emotions) and emotional expression (expressing adaptive emotions).  This 
scale has good internal consistency and validity (Stanton, Kirk, Cameron, & Danoff-
Burg, 2000; current sample: α = .85). 
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Outcome and Potentially Stigmatizing Measures 
There were two outcomes for this study, which coincide with the two primary 
goals. The first goal of this study was to develop predictors for concurrent substance 
abuse and specifically abuse of prescription opioids. The area of outcome for this goal 
was the substance use measures that are described in this section. The second goal of 
this study was to test whether participants shared different levels of stigmatized 
information as a function of the group to which they were assigned (private, traditional 
interview, enhanced interview). The areas of outcome for this goal were again the 
substance use measures and disclosure of stressful life events.  
Stressful life events. The Life Stressor Checklist-Revised (LSC-R; Wolfe, 
Kimerling, & Brown, 1993; Wolfe, Kimerling, Brown, Chresman & Levin, 1996) consists 
of 30 items assessing DSM-IV-TR criteria events for PTSD, in addition to non-DSM 
stressful life experiences. The items that describe PTSD life events include questions 
about the participant’s perception of harm or lethality, the intensity of their emotional 
reaction, and how much the event has affected them during the past year. The non-
PTSD questions ask about how much the stressful experience has affected the person 
over the past year. The LSC-R has demonstrated criterion-related validity for PTSD 
individuals with comorbid substance abuse and other psychological disorders (McHugo 
et al., 2005; Wolfe & Kimmerling, 1997).  The number of PTSD life events and the 
degree of distress participants continue to feel from these events was analyzed from 
this measure. Total number of events was calculated based on the number of the 30 
possible events that the participant endorsed as having experienced. Level of distress 
was calculated by averaging the current distress felt for each event (0- none at all to 5 – 
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extreme) across the events he or she experienced. This measure was part of the 
experimental portion of this study in that one-third of the participants filled this form out 
in the traditional written format. The other two-thirds of the participants were interviewed 
using this measure (a non-traditional method for use of this measure).  
Substance use, abuse and dependence. Use, abuse, and dependence on 
alcohol, prescription opioids, and other drugs were assessed using the Structured 
Clinical Interview for the DSM-IV-TR (SCID; First, Spitzer, Gibbon, & Williams, 2002; 
DSM-IV-TR: Diagnostic and Statistical Manual, version IV, text revision). Participants 
were randomized into one of the three groups to complete these measures. 
Prescription misuse. Prescription misuse was assessed using the Prescription 
Drug Use Questionnaire (PDUQ; Compton, Darakjian, & Miotto, 1998) as it provided the 
most comprehensive list of misuse symptoms and also has been developed to be used 
in either an interview or written format. The PDUQ consists of 31 items which address 
prescription misuse behaviors such as use of the medication to treat non-medically 
prescribed symptoms, doctor’s refusal to prescribe medication, disagreements with 
significant others over their prescription use, etc.  The PDUQ has shown good test-
retest reliability and criterion and predictive validity in chronic pain populations. The 
PDUQ has been shown to predict patients who later violate clinic policies related to 
prescription use and are forced to leave their treatment centers because of these 
violations (Compton, Wu, Schieffer, Pham, & Naliboff, 2008). The internal reliability of 
this measure for this sample was acceptably high for research purposes (α = .71). 
Evaluation of session. Participants were asked to rate items on a 1 to 7 scale, 
regarding their evaluation of their comfort sharing, the degree to which they withheld 
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sensitive information about trauma or substance use, and comfort with their interviewer 
(if they were in the standard or enhanced interview conditions).  
Data Analyses 
The data were checked for accuracy and frequency distributions of all items, and 
scored variables were examined for outlier values. Key missing data points were 
replaced through regressions using available measures. Skewed and outlier variables 
were transformed. The GSI was positively skewed and a log transformation successfully 
reduced the skewness. The SPS was skewed negatively and had a single low outlier. 
Inverse and log transformations were unsuccessful and thus the outlier was changed to 
the next lowest value in the dataset which successfully reduced the skewness. Finally, 
the BPI had a single high outlier and log transformations and square root 
transformations were unsuccessful in reducing it, the highest value was changed to the 
next highest value. The data was rechecked for skewness and kurtosis after all 
transformations and changes to the dataset. Internal consistency was assessed for all 
scales and reported in the description of each measure. Finally, the data was assessed 
for multicollinearity and the highest correlation between predictors was r = .65 (TAS-
TOT and AEQ-TOT), which is below the r = .70 cut-off suggested by Tabachnick and 
Fidell (2001) for multicollinearity in multivariate statistics (see Tables 4 and 5).  
Hypothesis 1. Hierarchical regressions were run to determine if higher levels of 
prescription misuse was associated with higher levels of alexithymia, higher emotional 
ambivalence, lower emotional approach coping, and more experience/impact of trauma, 
beyond traditional, pain, and cognitive/social factors. Prescription misuse is 
characterized by aberrant medication related behaviors that suggest risky decisions or 
50 
 
behaviors which may not meet the level of DSM-IV-TR symptomology. Prescription 
opioid misuse was operationalized as the total score on the Prescription Drug Use 
Questionnaire (PDUQ), which consisted of items such as requesting refills before a 
prescription should have run out, reporting that family members are worried about their 
prescription use, feeling as though their doctor does not give them enough medication, 
etc. Symptoms of abuse and dependence are characterized as meeting clinical criteria 
for problematic use. Total number of symptoms of abuse and dependence on 
prescription opioids was operationalized as the number of abuse and dependence 
symptoms reported on the SCID, which assesses DSM-IV-TR substance use disorder 
symptoms. Abuse is characterized by a single DSM-IV-TR abuse symptom during the 
past 12 months (abuse diagnosis is excluded if dependence criteria are met at any point 
in one’s lifetime) and dependence is characterized by any 3 DSM-IV-TR dependence 
symptoms occurring during the same 12-month period.  
These outcomes were zero-order correlated with each predictor measure, and to 
reduce the number of variables entered into the model, only those variables that were 
marginally or significantly correlated with prescription misuse and symptoms of abuse 
and dependence were entered into the regression.  
A hierarchical regression by blocks was conducted to determine whether emotion 
regulation measures increase predictive validity, in the following order (including only 
those variables from each block which were significantly zero-order correlated): 
assessment method group (as a control variable) demographic information/use history, 
pain variables, social/personality variables, and emotional variables. Personal history of 
substance use problems was excluded from all regressions because it was determined 
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that this characteristic: a) has strong research evidence that it is predictive of misuse 
and this study sought to determine additional factors that might predict for an individual 
who has never had misuse problems; b) it was determined that this characteristic likely 
inherently included the primary outcome of interest in that participants would respond 
positively to having a history of substance use problems if they believed they currently 
had a problem with their prescriptions. 
Additionally, hierarchical regressions were repeated using the same selected 
variables for demographic/traditional factors, pain, and social/personality, with each 
individual emotional variable (Toronto Alexithymia Scale, Ambivalence Over Emotional 
Expression, Emotional Approach Coping, and Impact of Events Scale). The purpose of 
these additional analyses was to explore the role of each emotional factor without 
controlling for the role of the other emotional factors. 
Personal history of substance use problems was excluded from the regression 
analyses for three reasons. First, the primary goal of the current study was to add to the 
theoretical understanding of what personal characteristics may increase the risk of 
engaging in prescription opioid misuse. Although personal history of substance use is 
likely pragmatically useful in identifying who should not be prescribed opioids, it does 
not add to the theoretical understanding of what personal characteristics make 
someone at higher risk of developing prescription misuse problems. There are 
hypothetically also instances in which participants may not have abused drugs prior to 
being prescribed an opioid, but understanding the personal characteristics that may put 
them at higher risk and engaging in prevention efforts may be valuable. There may also 
be instances in which patients are unlikely to admit to prior substance use history and 
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having an understanding of the other factors that may put those individuals in a higher 
risk category is essential. Second, there were measurement issues in the current study 
which made it difficult to determine whether prescription opioid misuse was treated as 
separate from prior substance use history in participants’ responses. Unfortunately, the 
wording of the question left open the possibility that some participants may have 
included ongoing prescription misuse in their answer of "yes" meaning that we would be 
controlling for the outcome we were trying to predict. Third, despite the strong prior 
evidence that prior history of substance use is related to prescription misuse, it only 
provides evidence that a past behavior predicts similar future behavior and for some 
participants it actually was opioids that they reported having problems with at some 
previous time and thus those participants were already experiencing problems 
controlling their behavior related to the same drug they are being medically provided. Of 
note, regressions were run controlling for personal history of substance use and it was 
found that none of the pain, social/cognitive, or emotional variables were significant, 
although emotional ambivalence had a marginal relationship with total number of 
prescription opioid abuse and dependence symptoms. 
Hypothesis 2. Hierarchical and logistic regressions were run to determine if 
higher levels of alcohol/illicit drug use were associated with higher levels of alexithymia, 
lower levels of emotional approach coping, and more experience/impact of trauma, 
beyond traditional, pain, and cognitive/social factors. Alcohol use was operationalized 
as the number of days out of the past 30 that participants reported drinking. Alcohol use 
was zero-order correlated with each predictor measure, and to reduce the number of 
variables entered into the model, only those variables that were marginally or 
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significantly correlated were included in the regression. As with prescription misuse, 
personal history of substance use was excluded from the regression model. A 
hierarchical regression by blocks was conducted to determine whether emotion 
regulation measures increase predictive validity, in the following order (including only 
those variables from each block which were significantly zero-order correlated): 
assessment method group (as a control variable), demographic information/use history, 
pain variables, social/personality variables, and emotional variables. Personal history of 
substance use problems was excluded from all regression models.  
Because fewer participants reported cannabis use than alcohol use, participants 
were dichotomously coded as users (1 or more days of use in the past 30 days) or non-
users (no use of cannabis in the past 30 days; see Table 5). Variables entered into the 
model were selected in the same way as days of alcohol use. A logistic regression was 
run to predict cannabis users and non-users. It should be noted that all other drug 
categories had too few active users to run a regression.  
Additionally, hierarchical and logistic regressions were repeated using the same 
selected variables for demographic/traditional factors, pain, and social/personality, with 
each individual emotional variable (Toronto Alexithymia Scale, Ambivalence Over 
Emotional Expression, Emotional Approach Coping, and Impact of Events Scale). The 
purpose of these additional analyses was to explore the role of each emotional factor 
without controlling for the role of the other emotional factors. 
Hypothesis 3. To determine if the three different conditions led to differing 
amounts of disclosure of aberrant use of prescription drugs, a 3-group ANOVA followed 
by Scheffe post-hoc tests was used to examine differences among disclosure methods 
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on the number of symptoms reported on the PDUQ, LSC-R, and number of symptoms 
of abuse/dependence on prescription opioids, alcohol, and all other drugs.  
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CHAPTER 3 
RESULTS 
Detailed Description of Pain and Substance History 
Pain condition. Most participants (n = 67; 67%) reported that a specific event 
such as a car accident, work related accident, or a fall led to at least one of their self-
reported pain conditions. The most common diagnoses were as follows: 70 with chronic 
back pain (70%), 25 with knee and leg pain (25%), 20 with arthritis (20%), 14 with 
degenerative disorders and neuropathy (14%),13 with head and neck pain (13%), 8 with 
abdominal pain (8%), 6 with fibromyalgia (6%), 6 with shoulder injuries (6%), and 5 with 
pinched nerves (5%). Note that the total is over 100 because many participants reported 
more than one pain condition. Participants had been experiencing their pain symptoms 
for an average of 12.93 years (SD = 11.09) 
Prescription use. The most common prescription medications were Vicodin (69 
participants; 69%), Tylenol 3 and Tylenol 4 (11 participants; 11%), and Oral Morphine 
(11 participants). Other medications included Dilaudid, Darvocet, Loritab, Methadone, 
Norco, and Oxycodone. Nearly half of the participants were prescribed more than one 
opioid pain medication (e.g., methadone and a shorter acting medication, oral pain 
prescription and a Fentanyl patch, etc.). Regarding the pain relief that participants 
reported experiencing from their medications, 79.2% of patients rated the pain relief as 
“5” or more on a scale of 1 to 10 (“1 no pain relief” to “10 complete pain relief”), but only 
10 participants reported that their medication was capable of removing their pain 
completely. The majority of the participants reported that they take their prescription 
daily (n = 83; 83%). A quarter (n = 25; 25%) of the participants had been taking their 
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current prescription for one year or less, and only 26 participants had been taking their 
current prescription for more than 5 years.  
Pain management. Participants reported a variety of treatments other than 
medication since their diagnosis: 82 participants reported trying physical therapy, 11 
reported engaging in psychological interventions for pain including individual treatment 
sessions and relaxation training, 10 reported having surgeries or nerve blocks, and 6 
reported getting massages or going to a chiropractor.  
Psychiatric and substance abuse history. Over half of the participants 
reported that they had been in psychiatric treatment at some point during their lives (n = 
55; outpatient therapy, inpatient treatment, etc.), and 53 participants reported that they 
had been prescribed a psychiatric medication (53%). Regarding family history, 35 
participants reported that one or more of their immediate family members had received 
psychiatric treatment (35%).  
Nearly a quarter of the participants reported that they had previously been in a 
substance abuse treatment program (n = 23). Nearly half of the participants reported 
that they believed they had a problem with drugs at some point in their life (n = 41) and 
21 participants reported a problem with alcohol. The most common drugs that 
participants reported having a past problem with were: cocaine (n = 11), heroin (n = 12), 
and marijuana (n = 11; see Table 3 for rates of past and current symptoms of abuse and 
dependence on alcohol and other drugs). Past research has shown that having a parent 
with a substance use problem can lead to a greater risk of substance use problems in 
their offspring. Many participants in this sample reported familial problems with alcohol 
or drugs: 11% father had problems with drugs (n = 11), 39% father had problems with 
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alcohol (n = 39), 12% mothers had problems with drugs (n = 12), 21% mother had 
problems with alcohol (n = 21), and 36% had a family member who had been in 
substance use treatment (n = 36). 
For all predictor and outcome measures used, see Table 1 and 2 below for mean 
and standard deviation values. 
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Table 1 Means and Standard Deviations of Predictor Measures 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Definitions of variable names – BSI.GSI (Global Severity Index of the Brief 
Symptom Inventory), BPI (Brief Pain Inventory, Severity Score), PCS-TOT (Total Score 
of the Pain Catastrophizing Scale), PASS-TOT (Total Score of the Pain Anxiety 
Symptom Scale), SPS-TOT (Total Score of the Social Provisions Scale), EXPECT 
(Belief that more medication is needed than other individuals from the Medication 
Beliefs Scale), TIPI-EXTRAV (Extraversion), TIPI-OPEN (Openness), TIPI-AGREE 
(Agreeableness), TIPI-CONSC (Conscientiousness), TIPI-STABLE (Emotional stability 
which is the inverse of neuroticism), TAS-TOT (Total Score of the Toronto Alexithymia 
Scale), AEQ-TOT (Total Score of the Ambivalence Over Emotional Expression Scale), 
IES-TOT (Total Score of the Impact of Events Scale), and EAC-TOT (Total Score of the 
Emotional Approach Coping Scale). Additional measures referred to throughout the 
study are: AODHx (personal history of alcohol or drug problems), ParentHx (parent 
history of alcohol or drug treatment) 
 Mean  Standard 
Deviation 
Basic   
    Age 47.57 11.57 
    BSI.GSI 1.25 0.86 
Pain   
    BPI 6.55 1.72 
    PCS-TOT 30.87 13.06 
    PASS-TOT 53.67 23.99 
Social/Cognitive   
    SPS-TOT 3.03 0.48 
    EXPECT 2.68 0.86 
    TIPI-EXTRAV 4.14 1.62 
    TIPI-OPEN 5.07 1.36 
    TIPI-AGREE 5.16 1.33 
    TIPI-CONSC 5.51 1.39 
    TIPI-STABLE 4.61 1.52 
Emotional   
    TAS-TOT 52.29 13.30 
    AEQ-TOT 3.02 0.95 
    IES-TOT 5.46 3.22 
    EAC-TOT 2.61 0.73 
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Table 2 Means and standard deviations M (SD) of continuous outcome measures 
and numbers and percentage n (%) of dichotomous variables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Categorical values which are displayed as n and percentage are italicized; 
continuous variables displayed as mean and standard deviations are not italicized. 
 Mean/#  Standard 
Deviation/
% 
Prescription Opioid 
Outcomes 
  
Prescription Drug  
    Use Questionnaire 
9.46 4.18 
Symptoms of  
    prescription abuse 
0.23 0.57 
Symptoms of  
    prescription  
    dependence 
1.36 1.44 
Total number of  
    abuse and  
    dependence  
    symptoms 
1.59 1.74 
# of participants  
    reporting any  
    abuse or dependence  
    symptoms 
67 67% 
Alcohol Outcome   
Days of alcohol use    
    out of past 30 days 
3.17 6.94 
Alcohol user (any  
    use in the past 30  
    days) 
41 41% 
Cannabis Outcome   
Cannabis user (any  
    use in the past 30  
    days) 
25 25% 
Trauma Outcomes   
Life Stressors  
    Checklist # of  
    Events 
10.97 5.37 
Life Stressors  
    Checklist average  
    level of distress 
2.64 0.99 
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Hypothesis 1 
 Hypothesis 1 tested whether stress/emotional factors could predict prescription 
misuse (as measured by the total score of the Prescription Drug Use Questionnaire) 
and symptoms of prescription opioid abuse and dependence (as quantified by both 
number of DSM-IV-TR symptoms of abuse and dependence and the qualitative 
diagnosis of dependence) beyond the more routinely assessed predictive factors 
(demographic, pain-related, and cognitive/social). Assessment method group 
assignment was controlled for by entering it into the first block of all regression 
analyses. 
Overview of Hypothesis 1. Zero-order correlations were run to first understand 
the relationship of all predictor measures to the Prescription Drug Use Questionnaire 
and prescription opioid abuse and dependence symptoms. Second, based upon the 
significant zero-order correlations, partial correlations were run controlling for any 
significant traditional and/or pain predictors to determine if the correlations between 
Prescription Drug Use Questionnaire and the number of abuse and dependence 
symptoms on current prescription opioid medication to emotional variables remained 
once the effect of demographic and pain variables were parceled out. Partial 
correlations were run controlling for a) any significant traditional variables and/or pain 
variables; b) controlling for each of those traditional factors individually. Third, to reduce 
the number of variables entered into the regression models, regressions were run using 
only those variables that had at least a marginally significant relationship with the 
Prescription Drug Use Questionnaire total score, the number of prescription opioid 
symptoms of abuse and dependence, and the categorical definition of being dependent 
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on their prescription opioid. An exception to this process was that all emotional variables 
(Toronto Alexitymia Scale, Ambivalence Over Emotional Expression Scale, Impact of 
Events Scale, and Emotional Approach Coping Scale) were included in the models 
regardless of their zero-order correlations with the outcome because these variables 
were of primary interest. Hierarchical regressions were run for the total score of the 
Prescription Drug Use Questionnaire and the total number of abuse and dependence 
symptoms and a logistic regression was run for diagnosis of dependence. Finally, 
regressions were repeated individually for each emotional predictor so that the effect of 
each emotional variable could be examined without controlling for the other emotional 
variables.  
Predicting scores on the Prescription Drug Use Questionnaire.  Participants 
reported a mean score of 9.46 (SD = 4.18) on the Prescription Drug Use Questionnaire 
total score. Only 7 participants reported that they had used their prescription medication 
to “feel high” (7%). Forty-nine (49%) of participants had scores at or higher than the cut-
off (i.e., a score of 10 or higher) established for probable problematic use of prescription 
medication (Compton et  al., 2008). 
Zero-order correlations of predictors with the Prescription Drug Use 
Questionnaire. Correlations between the predictors and total score of the Prescription 
Drug Use Questionnaire can be seen in Table 6. Personal history of alcohol or drug use 
problems, parental history of alcohol or drug use treatment, increased symptoms as 
measured by the Global Severity Index of the Brief Symptom Inventory, higher total 
scores on the Toronto Alexithymia Scale, and higher total scores on the Ambivalence 
Over Emotional Expression Scale were significantly correlated with higher total scores 
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on the Prescription Drug Use Questionnaire. Additionally, there was a trend suggesting 
that lower levels of extraversion were related to higher reports of prescription misuse. It 
is important to note that none of the pain variables were significantly correlated with the 
Prescription Drug Use Questionnaire (see Table 6). 
Partial correlations of predictors with the Prescription Drug Use 
Questionnaire. Variables that were significantly zero-order correlated with prescription 
misuse (parental history of alcohol or drug use treatment, Global Severity Index of the 
Brief Symptom Inventory/psychiatric symptoms) were entered as control variables in 
partial correlations of all social/cognitive and emotional factors with the Prescription 
Drug Use Questionnaire (see Table 7). None of the social/cognitive or emotional 
variables remained significant after controlling for these variables all at once or when 
parental history of alcohol or drug use treatment and Global Severity Index of the Brief 
Symptom Inventory were controlled for separately.  
Hierarchical regression predicting the Prescription Drug Use Questionnaire 
with all emotional variables. A hierarchical regression model composed of the 
following blocks of variables was conducted: control (assessment method group), 
traditional factors (parental history of alcohol or drug use treatment and psychiatric 
symptoms), social/cognitive factors (extraversion), and emotional factors (because 
these variables were of specific interest, all were included in the model). The regression 
was significantly predictive of the Prescription Drug Use Questionnaire total score, (R2 = 
.24, F(8, 91) = 3.65, p < .01; see Table 8). However, emotional variables did not explain 
a significant increase in variance from the control, traditional, and social/cognitive 
factors alone (p = .34). Having a family history of substance use problems significantly 
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predicted increased prescription misuse as measured by the Prescription Drug Use 
Questionnaire, β = .35, t(91) = 3.73, p < .001. Additionally, there was a trend for higher 
total scores on the Ambivalence Over Emotional Expression Scale as predictive of 
increased prescription misuse, β = .23, t(91) = 1.79, p = .08. 
Hierarchical regression predicting the Prescription Drug Use Questionnaire 
with each emotional variable independently. A hierarchical regression model 
composed of the following blocks of variables was conducted: control (assessment 
method group), traditional factors (parental history of alcohol or drug use treatment and 
psychiatric symptoms), social/cognitive (extraversion) and each emotional factor 
individually. 
Toronto Alexithymia Scale total score. The regression was significantly predictive 
of the Prescription Drug Use Questionnaire total score, (R2 = .21, F(5, 94) = 5.05, p < 
.01; see Table 8). However, alexithymia did not explain a significant increase in 
variance from the control, traditional, and social/cognitive factors alone (p = .37), even 
without controlling for other emotional characteristics. 
Ambivalence Over Emotional Expression total score. The regression was 
significantly predictive of the Prescription Drug Use Questionnaire total score, (R2 = .24, 
F(5, 94) = 5.84, p < .01; see Table 8), and the addition Ambivalence Over Emotional 
Expression explained a significant increase in variance from the control, traditional, and 
social/cognitive factors alone (∆R2 = .03, p < .05). Higher total scores on the 
Ambivalence Over Emotional Expression Scale were related to increased scores on the 
Prescription Drug Use Questionnaire, β = .22, t(94) = 1.99, p < .05. Thus, once 
removing the other emotional variables from the regression, higher levels of 
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Ambivalence Over Emotional Expression became a significant predictor for prescription 
misuse.  
Impact of Events Scale total score. The regression was significantly predictive of 
the Prescription Drug Use Questionnaire total score, (R2 = .21, F(5, 94) = 4.89, p < .01; 
see Table 8). However, the Impact of Events Scale did not explain a significant increase 
in variance from the control, traditional, and social/cognitive factors alone (p = .66), even 
without controlling for other emotional variables.  
Emotional Approach Coping total score. The regression was significantly 
predictive of the Prescription Drug Use Questionnaire total score, (R2 = .21, F(5, 94) = 
4.97, p < .01; see Table 8). However, the Emotional Approach Coping total score did 
not explain a significant increase in variance from the control, traditional, and 
social/cognitive factors alone (p = .47), even without controlling for other emotional 
characteristics. 
In summary, for prescription misuse as measured by the Prescription Drug Use 
Questionnaire, Hypothesis 1 was only partially supported. Higher scores on the 
Ambivalence Over Emotional Expression scale were significantly predictive of increased 
prescription misuse; however, no relationship existed between alexithymia, trauma, or 
the Emotional Approach Coping Scale and prescription misuse after controlling for 
assessment method group assignment, family history of substance use treatment, 
psychiatric symptoms and extraversion. 
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Table 6 Correlations of predictors and prescription drug misuse and symptoms of 
abuse and dependence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level. 
Trends (.05 - .10) are denoted by the † symbol. See Table 1 for variable definitions. 
Current dependence was coded as 1 = current dependence diagnosis; 0 = no current 
dependence diagnosis. 
 
 
 Prescription 
Drug Use 
Questionnaire  
Abuse and 
Dependence 
Symptoms 
Current 
Dependence on 
Prescription 
(Y/N) 
Basic    
    Age       .04 .18  .11 
    Sex      -.08 -.05 -.08 
    AODHx       .47**     .27**      .27** 
    ParentHx       .35**   .21*   .19† 
    BSI.GSI       .26** .05  .09 
Pain    
    BPI      -.01 .08  .15 
    PCS-TOT       .12 .14  .13 
    PASS-TOT       .17 .16    .21* 
Social/Cognitive    
    SPS-TOT      -.10  -.02 -.08 
    EXPECT       .15           -.01  -.01 
    TIPI-EXTRAV      -.17†   .02 -.07 
    TIPI-OPEN      -.13  -.17† -.06 
    TIPI-AGREE      -.14 -.15 -.03 
    TIPI-CONSC      -.16 -.09 -.10 
    TIPI-STABLE (N)      -.03   -.21*   -.20* 
Emotional    
    TAS-TOT       .21* .12  .18† 
    AEQ-TOT       .31**    .29**  .18† 
    IES-TOT       .16 .14   .21* 
    EAC-TOT      -.12 -.01 .04 
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Table 7        Partial correlations of predictors and prescription drug misuse and 
symptoms of abuse and dependence after controlling for traditional and pain variables 
significantly correlated with each outcome measure* 
 
 
 
 
 
 
 
 
 
 
Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level. 
See Table 1 for variable definitions. Current dependence was coded as 1 = current 
dependence diagnosis; 0 = no current dependence diagnosis. See Table 1 for variable 
definitions. *Partials for the Prescription Drug Use Questionnaire were controlled for by 
family history of alcohol or drug treatment and psychiatric symptoms. Abuse and 
dependence symptoms were controlled for by family history of drug or alcohol treatment 
only. Current dependence on prescription opioids was controlled for by family history of 
drug or alcohol treatment and the Pain Anxiety Symptom Scale. 
 Prescription 
Drug Use 
Questionnaire  
Abuse and 
Dependence 
Symptoms 
Current 
Dependence on 
Prescription 
(Y/N) 
Social/Cognitive    
    SPS-TOT .18 -.03 -.02 
    EXPECT .11 -.01 -.04 
    TIPI-EXTRAV         -.24  .01 -.06 
    TIPI-OPEN .29     -.21** -.04 
    TIPI-AGREE -.09 -.16 -.03 
    TIPI-CONSC .08 -.08 -.04 
    TIPI-STABLE (N) .13 -.19 -.12 
Emotional    
    TAS-TOT -.14  .11  .07 
    AEQ-TOT -.05      .27**  .06 
    IES-TOT -.17  .13  .11 
    EAC-TOT -.05 -.01  .04 
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Table 8 Predictors of prescription misuse (total score of the Prescription Drug Use 
Questionnaire) 
 All Emotional 
Variables 
  Each Emotional 
Variable Entered 
Separately 
 ∆R2 β  ∆R2 β 
Step 1 .01     
Group 
(control)  -.14 
 
  
   
 
  
Step 2 (Basic) .17**     
ParentHx   .35**    
BSI.GSI   .04    
   
 
  
Step 3 (Cog) .03†     
TIPI-Extrav  -.15    
   
 
  
Step 5 (Emo) .03     
TAS-Tot  -.03  .01  .11 
AEQ-Tot  
 .23†  .03†  .22* 
IES-Tot   .01  .01  .05 
EAC-Tot  -.09  .01 -.07 
 
Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level. 
Trends (.05 - .10) are denoted by the † symbol. See Table 1 for variable definitions.  
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Predicting symptoms of prescription opioid abuse and dependence. 
Regarding DSM-IV-TR criteria for abuse and dependence symptoms for their current 
prescription medications, the average number of symptoms was 1.59 (SD = 1.74), with 
the most common symptoms reported being: often using more than planned/prescribed 
(dependence symptom), repeated unsuccessful attempts to stop using (dependence 
symptom), withdrawal symptoms (dependence symptom), tolerance to the effects 
(dependence symptom), and feeling intoxicated while doing an important activity (abuse 
symptom; see Table 9 for number of participants reporting each symptom of abuse and 
dependence).  
Zero-order correlations of predictors with number of prescription opioid 
abuse and dependence symptoms. Personal history of alcohol or drug use problems, 
parental history of alcohol or drug use treatment, lower scores on emotional stability 
(low scores on emotional stability suggest higher levels of neuroticism) as measured by 
the Ten Item Personality Inventory, and higher total scores on the Ambivalence Over 
Emotional Expression Scale were significantly correlated with total number of 
prescription opioid abuse and dependence symptoms. There was a trend for lower 
levels of openness to correlate with an increased number of symptoms. None of the 
pain variables were significantly correlated with the number of abuse and dependence 
symptoms (see Table 6).  
Partial correlations of predictors with the symptoms of prescription opioid 
abuse and dependence. After determining the traditional (parental history of alcohol or 
drug use treatment) and pain factors (none) that were significantly zero-order correlated 
with the total number of symptoms, that variable was entered as a control variable in a 
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partial correlation of the total number of current abuse and dependence symptoms on 
prescription opioids and all social/cognitive and emotional variables. After controlling for 
family history, as predicted, higher scores on the Ambivalence over Emotional 
Expression Scale were correlated with more symptoms of abuse and dependence on 
prescription opioid medications. Additionally, lower levels of openness were also 
correlated with higher numbers of symptoms (see Table 7).  
Hierarchical regression predicting the total number of symptoms of 
prescription opioid abuse and dependence with all emotional variables. A 
hierarchical regression model composed of the following blocks of variables was 
conducted: control (assessment method group), traditional factors (parental history of 
alcohol or drug use treatment), social/cognitive factors (emotional stability and 
openness), and emotional factors (because these variables were of specific interest, all 
were included in the model). The regression was significantly predictive of total number 
of symptoms of prescription opioid abuse and dependence, (R2 = .24, F(8, 91) = 3.68, p 
< .01; see Table 10). However, the emotional variables did not explain a significant 
increase in variance from the control, traditional, and social/cognitive factors alone (p = 
.39). Having a family history of substance use problems was significantly predictive of a 
higher number of abuse and dependence symptoms, β = .26, t(91) = 2.68, p < .01. 
Additionally, there was a trend for higher total scores on the Ambivalence Over 
Emotional Expression Scale as predictive of increased prescription misuse, β = .26, 
t(91) = 1.97, p = .05. Thus, when all emotional variables are controlled for in the 
regression model, the only variable that has a marginal relationship with the number of 
abuse and dependence symptoms is ambivalence.  
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Hierarchical regression predicting the total number of prescription opioid 
abuse and dependence symptoms with each emotional variable independently. A 
hierarchical regression model composed of the following blocks of variables was 
conducted: control (assessment method group), traditional factors (parental history of 
alcohol or drug use treatment), social/cognitive factors (emotional stability and 
openness), and each emotional factor individually. 
Toronto Alexithymia Scale total score. The regression was significantly predictive 
of total number of prescription abuse and dependence symptoms, (R2 = .21, F(5, 94) = 
5.02, p < .01; see Table 10). However, it was found that the alexithymia did not explain 
a significant increase in variance from the control, traditional, and social/cognitive 
factors (p = .71), even without controlling for other emotional characteristics. 
Ambivalence Over Emotional Expression total score. The regression was 
significantly predictive of total number of prescription abuse and dependence 
symptoms, (R2 = .24, F(5, 94) = 5.79, p < .01; see Table 10) and the addition of the 
emotional variable block explained a marginal increase in variance from the control, 
traditional, and social/cognitive factors alone (∆R2 = .05, p = .08). Higher total scores on 
the Ambivalence Over Emotional Expression Scale were marginally related to higher 
total number of abuse and dependence symptoms, β = .18, t(94) = 1.79, p = .08. Thus, 
once removing the other emotional variables from the regression, higher scores on the 
Ambivalence Over Emotional Expression Scale became a marginal predictor for total 
number of abuse and dependence symptoms.  
Impact of Events Scale total score. The regression was significantly predictive of 
total number of prescription abuse and dependence symptoms, (R2 = .21, F(5, 94) = 
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5.01, p < .01; see Table 10). However, trauma symptoms did not explain a significant 
increase in variance from the control, traditional, and social/cognitive factors (p = .75), 
even without controlling for other emotional characteristics within the model. 
Emotional Approach Coping total score. The regression was significantly 
predictive of total number of prescription abuse and dependence symptoms, (R2 = .21, 
F(5, 94) = 5.01, p < .01; see Table 10). However, emotional approach coping did not 
explain a significant increase in variance from the control, traditional, and 
social/cognitive factors (p = .71), even in the absence of controlling for the other 
emotional variables. 
In summary, regarding the continuous measure of number of DSM-IV-TR abuse 
and dependence symptoms for prescription opioids, Hypothesis 1 was only partially 
supported. Higher scores on the Ambivalence Over Emotional Expression scale were 
marginally predictive of total number of prescription abuse and dependence symptoms; 
however, no relationship existed between alexithymia, trauma, or emotional approach 
coping and the total number of prescription opioid abuse and dependence symptoms 
after controlling for assessment method assignment, family history of substance abuse 
treatment, openness to experience, and emotional stability. 
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Table 9 Symptoms of abuse and dependence reported for prescription opioids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Abuse symptoms are based on report of recurrence of each item, not a single 
incident; diagnosis of current abuse is determined by the occurrence of any one of the 
abuse symptoms during the past 12 month period without ever meeting criteria for 
dependence; diagnosis of current dependence is determined by the occurrence of any 3 
of the dependence symptoms during the past 12 months 
 
 
 Number of 
Participants  
Percentage of 
Participants 
Abuse   
Intoxicated during  
    important  
    activities 
12 12% 
Using during risky  
    activities (e.g.,  
    driving) 
6 6% 
Legal problems  
    related to use 
3 3% 
Social or  
    interpersonal  
    problems 
5 5% 
Dependence    
Tolerance 12 12% 
Withdrawal 31 31% 
Using more than   
    planned 
20 20% 
Unsuccessful desire  
    to quit 
33 33% 
Great deal of time   
    using 
4 4% 
Interference with  
    activities 
8 8% 
Continued use  
    despite harm 
10 10% 
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Table 10 Predictors of total number of current prescription opioid symptoms of 
abuse and dependence 
 All Emotional 
Variables 
  Emotional 
Variables Entered 
Separately 
 ∆R2 β  ∆R2 β 
Step 1 .08**     
Group 
(control)  -.32** 
 
  
   
 
  
Step 2 (Basic) .07**     
ParentHx   .26*    
   
 
  
Step 3 (Cog) .05*     
TIPI-Open  -.14    
TIPI-Stable  -.09    
   
 
  
Step 4 (Emo) .04   .01  
TAS-Tot  -.12  .01   .04 
AEQ-Tot  
 .26†  .03†   .18† 
IES-Tot  -.03  .01   .03 
EAC-Tot  -.05  .01  -.04 
 
Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level. 
Trends (.05 - .10) are denoted by the † symbol. See Table 1 for variable definitions. 
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Predicting diagnosis of opioid dependence. Eight participants met criteria for 
current abuse of their prescription medication using DSM-IV-TR criteria and an 
additional 18 participants met criteria for current dependence of their prescription 
medication (see Table 3).  
Zero-order correlations of predictors with diagnosis of opioid dependence. 
Personal history of alcohol or drug problems, parental history of alcohol or drug use 
treatment, higher total score on the Pain Anxiety Symptom Scale, lower levels of 
emotional stability (indicative of neuroticism), and higher levels of trauma symptoms (as 
measured by the total score from the Impact of Events Scale) were significantly 
correlated with increased probability of meeting diagnostic criteria for current 
prescription opioid dependence. Additionally, higher scores on the Toronto Alexithymia 
Scale and the Ambivalence Over Emotional Expression Scales were marginally 
predictive of meeting diagnostic criteria for prescription opioid dependence (see Table 
6). 
Partial correlations of predictors with diagnosis of opioid dependence.  
Parental history of alcohol or drug use treatment and Pain Anxiety Symptom Scale total 
score were entered as control variables in a partial correlation of all social/cognitive and 
emotional variables and whether or not each participant met criteria for prescription 
opioid dependence. None of the social/cognitive or emotional variables remained 
significant after controlling for these variables (see Table 7).  
Logistic regression predicting diagnosis of opioid dependence with all 
emotional variables. A logistic regression model composed of the following blocks of 
variables was conducted: control (assessment method group), traditional factors 
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(parental history of alcohol or drug use treatment), pain (Pain Anxiety Symptoms Scale), 
social/cognitive factors (emotional stability), and emotional factors (because these 
variables were of specific interest, all were included in the model). The full model 
containing all predictors was statistically significant, Χ2 (7, N = 100) = 17.60, p = .02, 
indicating that the model was able to distinguish between participants who reported 
symptoms consistent with a diagnosis of prescription opioid dependence and those who 
did not (see Table 11). The model as a whole correctly classified 80.0% of cases who 
were opioid dependent. Only one of the independent variables made a unique 
statistically significant contribution to the model, family history of alcohol or drug 
treatment, with an odds ratio of 3.82, which indicated that participants who had a family 
history of drug treatment were almost 4 times more likely to have diagnosis of 
prescription opioid dependence than participants without a family history.  
Logistic regression predicting diagnosis of opioid dependence with each 
emotional variable independently. A logistic regression model composed of the 
following blocks of variables was conducted: control (assessment method group), 
traditional factors (parental history of alcohol or drug use treatment), social/cognitive 
factors (emotional stability and openness), and each emotional factor individually. 
Consistent with the results of the full logistic model, family history of drug or alcohol 
treatment remained the only significant predictor of diagnosis of prescription opioid 
dependence, with participants who had a family history of drug treatment having been 
nearly 4 times more likely to report symptoms consistent with a diagnosis of prescription 
opioid dependence. See Table 11 for all values.  
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In summary, regarding the dichotomous measure of whether or not participants 
reported symptoms consistent with a diagnosis of dependence on prescription opioids, 
Hypothesis 1 was not supported. Only family history of drug or alcohol treatment was 
predictive of a diagnosis of prescription opioid dependence. None of the emotional 
variables explained unique variance in the model after controlling for assessment 
method assignment, family history of drug or alcohol treatment, Pain Anxiety Symptom 
Scale total score, and emotional stability.  
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Table 11 Predictors of current diagnosis of prescription opioid dependence 
 
All Emotional 
Variables 
   
Emotional Variables 
Entered Separately 
Χ
 2 Values for Full 
Models of 
Emotional 
Variables Entered 
Separately 
 
B(SE B) eB Χ 2  B(SE B) eB Χ 2 
 
Step 1         
Group 
(control) 
-1.02 (0.42)* 0.36       
Step 2 (Basic)         
ParentHx  1.34  (0.62)* 3.82       
Step 3 (Pain)         
PASS-Tot  0.01 (0.02) 1.01       
Step 4 (Cog)         
TIPI-Stability -0.26 (0.23) 0.77       
Step 5 (Emo)         
TAS-Tot  0.01 (0.03) 1.01     0.02 (0.03) 1.02 16.90**  
AEQ-Tot -0.15 (0.45) 0.86     0.05  (0.38) 1.06 16.63**  
IES-Tot  0.11 (0.14) 1.11     0.11 (0.12) 1.11 17.40**  
EAC-Tot -0.02 (0.44) 0.98 17.60*   -0.01 (0.41) 1.00 16.61*  
 
Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level. 
Trends (.05 - .10) are denoted by the † symbol. Significance of individual variables 
determined by the Wald’s test. See Table 1 for variable definitions.  
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Hypothesis 2 
Hypothesis 2 tested the hypothesis that stress/emotional factors could predict 
alcohol and other drug use beyond the more routinely assessed predictive factors 
(demographic, pain-related, cognitive/social, and stress/emotional factors). The two 
outcome categories were alcohol and cannabis as they were the most frequently 
reported drugs of abuse. For alcohol, both a categorical value of current user versus not 
a current user (any days of use during the past month) and a continuous measure of the 
number of days of use during the last month (to assess degree of current use) were 
evaluated. Because there were fewer participants reporting use of cannabis, only the 
categorical variable of “user” versus “non-user” was evaluated in a logistic regression. 
Use was operationalized as either “users” who had used 1 or more days of use in the 
past 30 days or “non-users” who reported no use in the past 30 days for both alcohol 
and cannabis. 
Predicting Days of Alcohol Use. Participants reported a mean of 3.26 days (SD 
= 7.02) of drinking alcohol out of the past 30 days. Regarding DSM-IV-TR criteria for 
abuse and dependence symptoms for alcohol, the average number of symptoms was 
0.73 (SD = 2.01). Twenty-one participants met criteria for abuse of alcohol using DSM-
IV-TR criteria at any time in their lives (2 participants met criteria at the time of 
participation), and 24 participants met criteria for dependence on alcohol at any time in 
their lives (12 participants met criteria at the time of participation). It is important to note 
that a diagnosis of alcohol dependence at any time in a participant’s life excludes a 
diagnosis of abuse, thus more than 21 participants reported symptoms of abuse but had 
also reported symptoms consistent with a diagnosis of dependence and were excluded 
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from the abuse category. Correlations between the predictors and days of alcohol use 
out of the past 30 days and the categorical variable of current alcohol user versus non-
user are presented in Table 12. 
Zero-order correlations of predictors with days of alcohol use during the 
past 30 days. Personal history of alcohol or drug use problems, parental history of 
alcohol or drug use treatment, higher levels of psychiatric symptoms (as measured by 
the Brief Symptom Inventory Global Severity Index), higher scores on the Pain 
Catastrophizing Scale, lower scores on emotional stability (low scores on emotional 
stability suggest higher levels of neuroticism) as measured by the Ten Item Personality 
Inventory, lower scores on agreeableness (as measured by the Ten Item Personality 
Inventory), and higher total scores on the Ambivalence Over Emotional Expression 
Scale (see Table 12) were correlated with total days of alcohol use out of the past 30. 
Partial correlations of predictors with days of alcohol use during the past 
30 days. Parental history of alcohol or drug use treatment, higher levels of psychiatric 
symptoms, and total score on the Pain Catastrophizing Scale were entered as control 
variables in a partial correlation of all social/cognitive and emotional variables with the 
total days drinking alcohol during the past month. Lower scores on agreeableness 
remained significantly correlated with more days of drinking alcohol during the past 30 
days even after controlling for parental history of alcohol or drug use treatment, 
psychiatric symptoms, and the Pain Catastrophizing Scale (see Table 13).   
Hierarchical regression predicting the days of alcohol use during the past 
30 days with all emotional variables. A hierarchical regression model composed of 
the following blocks of variables was conducted: control (assessment method group), 
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traditional (parental history of alcohol or drug use treatment, higher levels of psychiatric 
symptoms), pain (Pain Catastrophizing Scale), social/cognitive factors (extraversion and 
agreeableness), and emotional factors (because these variables were of specific 
interest, all were included in the model).  
The regression was significantly predictive of total number days of alcohol use 
out of the past 30 days, (R2 = .24, F(10, 89) = 2.84, p < .01; see Table 14). As 
hypothesized, the emotional variables explained a significant increase in variance (∆R2 
= .09 p= .04). Higher scores on the Ambivalence Over Emotional Expression Scale 
were significantly predictive of more days of alcohol use, β = .29, t(89) = 2.09, p =.04, 
even after controlling for all other traditional, pain, social/cognitive, and emotional 
factors. Lower scores on the Toronto Alexithymia Scale were significantly associated 
with more days of alcohol use out of the past 30 (β = -.40, t(89) = -2.72, p < .01), 
however, this was not in the direction hypothesized. Higher scores on the Pain 
Catastrophizing Scale (β = .29, t(89) = 2.13, p = .04) was predictive of more days of 
alcohol use. Additionally, having a family history of alcohol or drug treatment (β = .19, 
t(89) = 1.93, p = .06) and lower levels of agreeableness were marginally predictive of 
more days drinking during the past month (β = -.21, t(89) = -1.88, p = .06; see Table 
14). 
Hierarchical regression predicting days of alcohol use in the past 30 days 
with each emotional variable independently. A hierarchical regression model 
composed of the following blocks of variables was conducted: control (assessment 
method group), traditional (parental history of alcohol or drug use treatment, higher 
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levels of psychiatric symptoms), pain (Pain Catastrophizing Scale), social/cognitive 
factors (extraversion and agreeableness), and each emotional factor individually. 
Toronto Alexithymia Scale total score. The regression was significantly predictive 
of total number days of alcohol use out of the past 30 days, (R2 = .19, F(7, 92) = 3.01, p 
< .01; see Table 12). As hypothesized, the emotional variables explained a significant 
increase in variance (∆R2 = .04 p= .04), however, it was not in the hypothesized 
direction. Lower scores on the Toronto Alexithymia Scale were significantly predictive of 
more days of drinking out of the past 30 (β = -.27, t(92) = -1.99, p < .05).  
Ambivalence Over Emotional Expression total score. The regression was 
significantly predictive of total number days of alcohol use out of the past 30 days, (R2 = 
.16, F(7, 92) = 2.45, p = .02; see Table 14). However, emotional ambivalence did not 
explain a significant increase in variance from the control, traditional, and 
social/cognitive factors alone (p = .41), in the absence of controlling for the other 
emotional variables. 
Impact of Events Scale total score. The regression was significantly predictive of 
total number of days drinking alcohol out of the past 30, (R2 = .18, F(7, 92) = 2.59, p = 
.02; see Table 14). However, trauma symptoms did not explain a significant increase in 
variance from the control, traditional, and social/cognitive factors alone (p = .17), even 
without controlling for other emotional characteristics within the model. 
Emotional Approach Coping total score. The regression was significantly 
predictive of total number of days drinking alcohol out of the past 30, (R2 = .16, F(7, 92) 
= 2.43, p = .03; see Table 14). However, the emotional variable block did not explain a 
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significant increase in variance from the control, traditional, and social/cognitive factors 
alone (p = .52), even in the absence of controlling for the other emotional variables.  
In summary, regarding the continuous measure of number of days drinking 
alcohol out of the past 30, Hypothesis 2 was only partially supported. Higher scores on 
the Ambivalence Over Emotional Expression scale were predictive of total days drinking 
alcohol out of the past 30 in the full model only, in which assessment method 
assignment, parent history of substance use treatment, psychiatric symptoms, 
medication expectations, agreeableness, emotional stability, and all other emotional 
characteristics were controlled. Additionally, there was a significant relationship 
between alexithymia and days of alcohol use in the opposite direction than 
hypothesized in both the full model and when the other emotional variables were not 
controlled for in the model. No relationship existed between total number of days 
drinking alcohol out of the past 30 and trauma or the Emotional Approach Coping Scale. 
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Table 12 Correlations of predictors and use of alcohol and cannabis during the past  
month 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level. 
Trends (.05 - .10) are denoted by the † symbol. See Table 1 for variable definitions. 
Alcohol use and cannabis use were coded as: 1 = use of alcohol/cannabis during the 
past 30 days; 0 = no use of alcohol/cannabis during the past 30 days. 
 
 
 
 
 
 
 
 
 Days of alcohol use 
last month (0 to 30 
scale) 
Alcohol use 
during the past 
month (Yes/No) 
Cannabis use 
during the past 
month (Yes/No) 
Basic 
   
    Age -.04  -.24**   -.28** 
    Sex -.06  -.11  .04 
    AODHx  .27**   .12  .01 
    ParentHx  .21*   .01  .01 
    BSI.GSI  .24**   .26** -.03 
Pain 
   
    BPI  .09   .10 -.07 
    PCS-TOT  .25**   .27**  .01 
    PASS-TOT  .19   .17  .06 
Social/Cognitive 
   
    SPS-TOT -.15  -.29**  .06 
    EXPECT  .12   .12  .05 
    TIPI-EXTRAV -.05  -.11 
  .18† 
    TIPI-OPEN -.07  -.06  .02 
    TIPI-AGREE -.22* 
 -.18†  .12 
    TIPI-CONSC -.17  -.21*  .08 
    TIPI-STABLE -.22*  -.20* -.05 
Emotional 
   
    TAS-TOT   .08   .16  -.05 
    AEQ-TOT   .28**   .28** -.13 
    IES-TOT   .08   .21*   .03 
    EAC-TOT  -.09   .04   .11 
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Table 13  Partial correlations of predictors and use of alcohol and cannabis 
controlling for traditional and pain variables that significantly correlated with each 
outcome measure* 
 
 
 
 
 
 
 
 
Note: *Correlations for days of alcohol use were controlled by parent history of alcohol 
or drug treatment, BSI.GSI, and PCS-TOT. Correlations for alcohol use were controlled 
for by age, BSI.GSI, and PCS-TOT. Correlations for cannabis use were controlled for by 
age. Significant correlations at the .05 level are denoted by * and by ** at the .01 level. 
Trends (.05 - .10) are denoted by the † symbol. See Table 1 for variable definitions. 
Alcohol use and cannabis use were coded as: 1 = use of alcohol/cannabis during the 
past 30 days; 0 = no use of alcohol/cannabis during the past 30 days. 
 
 
 
 
 
 
 
 
 Days of alcohol 
use last month (0 
to 30 scale) 
Alcohol use 
during the past 
month (Yes/No) 
Cannabis use 
during the past 
month (Yes/No) 
Social/Cognitive 
   
    SPS-TOT -.02 -.17  .12 
    EXPECT  .07  .07  .05 
    TIPI-EXTRAV  .03 -.04   .21* 
    TIPI-OPEN  .01  .03  .06 
    TIPI-AGREE -.20* -.14  .16 
    TIPI-CONSC -.08 -.08 
   .18† 
    TIPI-STABLE -.07 -.05  .02 
Emotional 
   
    TAS-TOT -.17 -.07 -.11 
    AEQ-TOT  .10  .14 -.15 
    IES-TOT -.13  .01 -.05 
    EAC-TOT -.06  .09  .16 
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Table 14 Hierarchical regression of days of use of alcohol during the past month 
 
All Emotional 
Variables 
  Emotional Variables 
Entered Separately 
 ∆R2 β  ∆R2 β 
Step 1 .01     
Group 
(control) 
  .01    
   
 
  
Step 2 (Basic) .10**     
ParentHx  
 .19†    
BSI.GSI   .13    
   
 
  
Step 3 (Pain) .02     
PCS-TOT   .29*    
 
  
 
  
Step 3 (Cog) .04     
TIPI-Agree  -.21†    
TIPI-Stable  -.04    
   
 
  
Step 4 (Emo) .09*     
TAS-Tot  -.40*  .04*  -.27* 
AEQ-Tot   .29*  .01   .11 
IES-Tot  -.14  .01  -.15 
EAC-Tot  -.11  .01  -.07 
 
Note: † denotes marginal significance (.05 to .10), * denotes significance at the .05 level, 
** denotes significance at the .01 level. See Table 1 for variable definitions. 
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Predicting alcohol users versus non-users. Forty-one (41%) of participants 
were classified as alcohol users during the past month, which was defined as one or 
more days drinking alcohol during the past 30 days (see Table 3).  
Zero-order correlations of predictors with being a current alcohol user. 
Younger age, more psychiatric symptoms (as measured by the Brief Symptom 
Inventory Global Severity Index), higher total score on the Pain Catastrophizing Scale, 
lower seeking of social support (as measured by the Social Provisions Scale), lower 
levels of emotional stability (indicative of neuroticism), lower levels of 
conscientiousness, higher scores on the Ambivalence Over Emotional Expression 
Scale, and higher levels of trauma symptoms (as measured by the total score from the 
Impact of Events Scale) were significantly related to increased probability of being a 
current alcohol user. Additionally, lower scores on agreeableness were marginally 
predictive being a current alcohol user (see Table 12). 
Partial correlations of predictors being a current alcohol user.  Age, 
psychiatric symptoms, and total scores on the Pain Catastrophizing Scale were entered 
as control variables in a partial correlation of all social/cognitive and emotional variables 
and whether or not each participant was an alcohol user. None of the social/cognitive or 
emotional variables remained significant after controlling for the traditional/demographic 
and pain variables (see Table 13).  
Logistic regression predicting being a current alcohol user. A logistic 
regression model composed of the following blocks of variables was conducted: control 
(assessment method group), traditional factors (age, psychiatric symptoms), pain (Pain 
Catastrophizing Scale), social/cognitive factors (Social Provisions Scale, 
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agreeableness, conscientiousness, emotional stability), and emotional factors (because 
these variables were of specific interest, all were included in the model). The full model 
containing all predictors was statistically significant, Χ2 (12, N = 100) = 24.39, p = .02, 
indicating that the model was able to distinguish between participants who were current 
alcohol users and those who were not. The model as a whole correctly classified 72.0% 
of cases as current alcohol users. Only one of the independent variables made a unique 
statistically significant contribution to the model: younger age (see Table 15). For each 
year a participant was older, the odds of that participant being a current alcohol user 
decreased from 1 to 0.95. 
Logistic regression predicting being a current alcohol user with each 
emotional variable independently. A logistic regression model composed of the 
following blocks of variables was conducted: control (assessment method group), 
traditional factors (age, psychiatric symptoms), pain (Pain Catastrophizing Scale), 
social/cognitive factors (Social Provisions Scale, agreeableness, conscientiousness, 
emotional stability), and each emotional factor individually. Consistent with the results of 
the full logistic model, younger age remained the only significant predictor of being a 
current alcohol user. See Table 15 for all values.  
Regarding the dichotomous measure of whether or not participants were current 
alcohol users, Hypothesis 2 was not supported. Only younger age significantly predicted 
whether or not someone was a current alcohol user. None of the emotional variables 
explained unique variance in the model after controlling for assessment method, age, 
psychiatric symptoms, total score on the Pain Catastrophizing Scale, agreeableness, 
conscientiousness, and emotional stability. 
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Table 15 Logistic regression of current alcohol user versus non-user   
 
All Emotional 
Variables 
   
Emotional Variables 
Entered Separately 
Χ
 2 Values for Full 
Models of 
Emotional 
Variables Entered 
Separately 
 
B(SE B) eB  Χ 2 B(SE B) eB Χ 2 
Step 1         
Group 
(control) 
-0.37 (0.29) 0.69       
Step 2 (Basic)         
Age -0.05 (0.02)* 0.95       
BSI.GSI 0.31 (0.43) 1.36       
Step 3 (Pain)         
PCS-Tot 0.03 (0.03) 1.03       
Step 4 (Cog)         
SPS-Tot -0.87 (0.60) 0.42       
TIPI-AGREE -0.23 (0.22) 0.79       
TIPI-CONSC 0.05 (0.22) 1.05       
TIPI-STABLE 0.01 (0.21) 1.01       
Step 5 (Emo)         
TAS-Tot -0.03 (0.03) 0.97   -0.03 (0.02) 0.98 21.68**  
AEQ-Tot 0.49 (0.36) 1.62    0.26 (0.31) 1.30 21.22**  
IES-Tot -0.42 (0.10) 0.96   -0.01 (0.10) 1.00 20.54*  
EAC-Tot 0.31 (0.37) 1.37  24.39**  0.38 (0.34) 1.46 21.80**  
 
Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level. 
Trends (.05 - .10) are denoted by the † symbol. Significance of individual variables 
determined by the Wald’s test. See Table 1 for variable definitions. Alcohol use was 
coded as: 1 = use of alcohol during the past 30 days; 0 = no use of alcohol during the 
past 30 days. 
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Cannabis use. Participants reported a mean of 4.77 days (SD = 10.29) of using 
cannabis out of the past 30 days. Regarding DSM-IV-TR criteria for abuse and 
dependence symptoms for cannabis, the average number of current symptoms was 
1.02 (SD = 2.06). Thirteen participants met criteria for abuse of cannabis using DSM-IV-
TR criteria at any time in their lives (5 participants met criteria at the time of 
participation) and an additional 22 participants met criteria for dependence on cannabis 
at any time in their lives (12 participants met criteria at the time of participation; see 
Table 3).  
Zero-order correlations of predictors with being a current cannabis user. 
Younger age was significantly correlated with an increased probability of being a current 
cannabis user. Additionally, higher scores on extraversion were marginally predictive of 
being a current cannabis user (see Table 12).  
Partial correlations of predictors being a current cannabis user.  Age was 
entered as a control variable in a partial correlation of all social/cognitive and emotional 
variables with whether or not each participant was a cannabis user. Higher levels of 
extraversion became significant after controlling for age (see Table 13).  
Logistic regression predicting being a current cannabis user. A logistic 
regression model composed of the following blocks of variables was conducted: control 
(assessment method group), traditional factor (age), social/cognitive factor 
(extraversion), and emotional factors (because these variables were of specific interest, 
all were included in the model). The full model containing all predictors was statistically 
significant, Χ2 (7, N = 100) = 19.00, p < .01, indicating that the model was able to 
distinguish between participants who were current cannabis users and those who were 
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not. The model as a whole explained correctly classified 82.0% of cases as current 
cannabis users. Only one of the independent variables made a unique statistically 
significant contribution to the model: younger age (see Table 16). For each year older a 
participant was, his or her odds of being a cannabis user was reduced by 0.93.  
Logistic regression predicting being a current cannabis user with each 
emotional variable independently. A logistic regression model composed of the 
following blocks of variables was conducted: control (assessment method group), 
traditional factor (age), social/cognitive factors (extraversion), and each emotional factor 
individually. Consistent with the results of the full logistic model, younger age remained 
the only significant predictor of being a current cannabis user. See Table 16 for all 
values.  
In summary, regarding the dichotomous measure of whether or not participants 
were current cannabis users, Hypothesis 2 was not supported. None of the emotional 
variables explained unique variance in the model after controlling for assessment 
method assignment, age, and extraversion. 
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Table 16 Logistic regression of current cannabis user versus non-user   
 All Emotional 
Variables 
  
Emotional Variables 
Entered Separately 
Χ
 2 Values for Full Models of 
Emotional Variables 
Entered Separately 
 
B(SE B) eB Χ 2 B(SE B) eB Χ 2 
Step 1        
Group 
(control) 
-0.55 (0.33) 0.58      
Step 2 (Basic)        
Age -0.08 (0.03)** 0.93      
Step 3 (Cog)        
TIPI-EXTRV 0.31 (0.19) † 1.37      
Step 5 (Emo)        
TAS-Tot 0.03 (0.03) 1.03  -0.01 (0.02) 0.99 15.12**  
AEQ-Tot -0.67 (0.41) 0.51  -0.44 (0.28) 0.64 17.39**  
IES-Tot -0.04 (0.11) 0.97  -0.05 (0.08) 0.95 15.20**  
EAC-Tot 0.45 (0.43) 1.57 19.00** 0.28 (0.37) 1.32 15.39**  
 
Note: Significant correlations at the .05 level are denoted by * and by ** at the .01 level. 
Trends (.05 - .10) are denoted by the † symbol. Significance of individual variables 
determined by the Wald’s test. See Table 1 for variable definitions. Cannabis use was 
coded as: 1 = use of cannabis during the past 30 days; 0 = no use of cannabis during 
the past 30 days. 
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Hypothesis 3 
Hypothesis 3 tested the difference in outcome measures by randomized data 
collection method (enhanced interview, standard interview, and written format). Prior to 
conducting the analyses, the success of randomization to the assessment method 
groups and researcher adherence to assessment method group method was evaluated.  
Testing the success of randomization. To determine whether groups were 
equivalent prior to randomization to the intervention (i.e., assigned assessment method 
group), baseline characteristics of demographics, pain severity, and medication 
effectiveness were conducted. The success of the randomization into assessment 
method groups was tested using a one-way ANOVA for continuous variables (age, BPI 
Total Pain, and Medication Effectiveness) and Chi-Square analyses for categorical 
variables (gender, ethnicity). Analyses indicated that there were no baseline differences 
among the experimental groups on demographic variables, level of self-reported pain, 
or self-reported medication effectiveness in managing pain (see Table 17), which 
suggests that groups were equivalent prior to randomization. 
Differences based on assessment method group assignment. To explore 
group differences on outcome variables a one-way ANOVA with assessment method 
group as a fixed factor was run (see Table 2 for all means and standard deviations). 
Hypothesis 3 was partially supported. Regarding prescription use, the enhanced group 
reported significantly more symptoms of abuse and dependence on their current pain 
prescription than the written group, F(2, 97) = 4.49, p = .01. No significant group 
differences were found for prescription misuse as measured by the total score of the 
Prescription Drug Use Questionnaire. Regarding other substances of abuse, the 
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enhanced and standard groups disclosed significantly more current symptoms of 
cannabis abuse and dependence (F(2, 97) = 5.55, p < .01) than the written group. No 
significant differences among assessment method groups existed for number of alcohol 
related symptoms or days of cannabis and alcohol use during the past month. 
Regarding trauma, the written group disclosed significantly more distress symptoms of 
the Life Stressors Checklist than the standard group, F(2, 97) = 5.70, p < .01. 
Additionally, the enhanced group reported marginally more PTSD symptoms than the 
written group, F(2,97) = 2.81, p = .07. Assessment method groups did not significantly 
differ on number of traumatic life events reported on the Life Stressors Checklist (see 
Table 18). 
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Table 17 Testing the Success of Randomization  
 
Note*: 5 participants did not report ethnicity and thus percentages for this category only 
are based on a total of 95 participants. See Table 1 for variable definitions 
 
 Enhanced  Standard  Written 
Age (in years) 48.00 (10.54) 48.97 (12.52) 45.89 (11.71) 
    
Gender (n, %) 
   
    Male 16 (48.5%) 15 (46.9%) 16 (45.7%) 
    Female 17 (51.5%) 17 (53.1%) 19 (54.3%) 
    
Ethnicity (n, %)* 
   
    European-American 5 (15.2%) 3 (10.3%) 3 (9.1%) 
    African-American 28 (84.8%) 26 (89.7%) 27 (81.8%) 
    Other  0 (0.0%) 0 (0.0%) 3 (9.1%) 
      
BPI Total Score 6.31 (1.51) 6.46 (1.81) 6.86 (1.82) 
Medication Effectiveness 6.69 (1.86) 7.42 (1.99) 6.60 (1.95) 
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Table 18 Data Collection Method Differences on Outcome Measures 
Note: Superscripts that do not match (e.g., a and b) denote groups that are significantly 
different from one another as determined by Scheffe post-hoc tests. See Table 1 for 
variable definitions.  
 
 Enhanced Standard Written F-value (p-value) 
Prescription 
Misuse      
PDUQ 10.12 (3.94) 8.75 (4.56) 9.49 (4.04) 0.87 .42 
Abuse/Depend       
    Rx Symptoms 2.15 (1.75) a 1.72 (2.05) ab 0.94 (1.19) b 4.49 .01 
      
Alcohol Use 
  
  
 
Days Alcohol   
    Use Month 3.15 (6.08) 3.50 (7.62) 3.14 (7.46) 0.03 .97 
Abuse/Depend    
    Alcohol    
    Symptoms 
0.76 (2.02) 0.91 (2.25) 0.54 (1.82) 0.27 .76 
      
Other Drug Use 
     
Days Cannabis   
    Use Month 5.91 (11.15) 6.09 (11.77) 2.49 (7.52) 1.34 .27 
Cannabis   
    Abuse/Depend 
    Symptoms 
1.33 (2.20)
 a 1.66 (2.61) a 0.14 (0.55) b 5.55 .01 
      
Trauma 
     
LSC Total  
    Events 12.24 (4.52) 11.16 (5.79) 9.54 (5.57) 2.22 .11 
LSC Distress 2.63 (0.95)ab 2.26 (0.86) a 3.05 (1.01) b 5.70 .01 
PTSDSx 7.06 (5.37) 6.69 (5.89) 4.09 (5.68) 2.81 .07 
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Discussion 
The present study first sought to determine which demographic, pain-related, 
cognitive/social, and stress/emotional factors predict and help to explain the abuse of 
prescription opioids among patients in treatment for chronic pain. It was hypothesized 
that the traditional, pain, social/cognitive, and emotional factors explored would be 
predictive of aberrant prescription opioid use, and that the knowledge of factors related 
to stress and emotion regulation would predict prescription misuse beyond more 
routinely assessed and established factors. Partial support was found for hypothesis 1. 
Personal and family histories of substance use problems were predictive of opioid use 
related problems and there was support for emotional ambivalence predicting above 
and beyond traditionally evaluated factors. There were inconsistent findings for the role 
of personality factors in predicting prescription opioid use problems. 
Second, it was hypothesized that the traditional, pain, social/cognitive, and 
emotional factors would also be predictive of alcohol and other drug use in this chronic 
pain population and that, again, the addition of emotion regulation factors to the model 
would explain above and beyond the other factors. Limited support was found for this 
hypothesis. Personal and family histories of substance use problems were predictive of 
more days of alcohol use during the past month, and emotional ambivalence again 
predicted above and beyond traditionally evaluated factors. However, only younger age 
predicted whether or not a participant was a current user of alcohol or cannabis. 
Third, this study sought to determine whether an innovative, clinically sensitive 
interview protocol would enhance disclosure beyond a traditional interview or a 
questionnaire by testing different methods of eliciting disclosure of stigmatized 
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information (misuse of prescription medication, use of alcohol/drugs, and experience of 
stressful events or traumas). It was predicted that participants in the enhanced group 
would disclose the most information regarding their prescription misuse, substance use 
and abuse, and trauma histories. Further, it was hypothesized that the questionnaire 
condition would lead to higher levels of disclosure than the standard interview group. 
Partial support was found for this hypothesis. The enhanced group reported more 
symptoms of abuse and dependence on their prescription opioids and cannabis than 
the written group. Participants in the enhanced group reported more experiences of 
trauma than the written group. Results regarding alcohol use, prescription misuse, and 
distress over trauma were not supportive of the role of the enhanced method in 
improving disclosure.  
Prediction of Prescription Opioid Use Related Problems  
The first hypothesis posited that knowledge of factors related to stress and 
emotion regulation would explain prescription misuse (as evidenced by Prescription 
Drug Use Questionnnaire Total scores) and/or prescription opioid abuse or dependence 
symptoms, beyond more routinely assessed and established factors.  Hypothesis 1 was 
partially supported.  
Describing prescription opioid use related problems in this sample. 
Prescription misuse is defined by risky behaviors related to one’s use of a prescription. 
Prescription misuse does not necessarily rise to the level of an abuse or dependence 
diagnosis. Examples of risky behaviors included on the Prescription Drug Use 
Questionnaire are visiting an emergency room in the past 6 months because of pain, 
running out of medication before expected, and using pain medicine to help with other 
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symptoms such as anxiety or difficulty sleeping (Compton et al., 2008). Previous 
research (Compton et al., 2008) showed a cutoff score of 10 or greater on the 
Prescription Drug Use Questionnaire was useful in predicting future clinic-imposed 
discontinuation of treatment resulting from patient violations of treatment contracts. 
Higher scores on the Prescription Drug Use Questionnaire are indicative of current risky 
and problematic behaviors, as well as a likely precursor to the development of an abuse 
or dependence diagnoses. Even in the absence of a clinical diagnosis of abuse or 
dependence, prescription misuse carries with it interpersonal and health-related risks. It 
is interesting to note that as compared to previous research, a higher number of 
participants in this study, 49% (n = 49), were  above the cutoff of 10 suggesting  
problematic prescription opioid use (Hojsted & Sjogren, 2007). 
Regarding reported symptoms of abuse and dependence, it is essential to review 
the actual symptoms reported to differentiate misuse from “pseudo-addiction.” “Pseudo-
addiction” refers to the expected development of physical dependence to opioids with 
ongoing, daily usage. Physical dependence refers to both tolerance to the drug’s effects 
(e.g., needing more medication to report feeling the same effect) and withdrawal when 
an individual stops using the medication (e.g., sweats, body aches, irritability, etc.; 
Weissman & Haddox, 1989). Symptoms of “pseudo-addiction” are inherent in chronic 
use of an opioid. Twelve (12%) participants noted tolerance and 31 (31%) reported 
withdrawal effects in the current study. However, other DSM-IV-TR symptoms of abuse 
and dependence are more consistent with aberrant medication use. Participants 
reported an average of 1.59 (SD = 1.74) abuse and dependence symptoms, and many 
participants reported symptoms other than tolerance and abuse. Eight (8%) participants 
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met criteria for current prescription opioid abuse, and an additional 18 (18%) met criteria 
for current prescription opioid dependence; neither of which participants could have met 
criteria for without reporting symptoms beyond tolerance and withdrawal. The number of 
participants meeting criteria for abuse or dependence of prescription medication has 
been debated in the field (Becker et al., 2008; Chabal et al., 1997; Cowan et al., 2003; 
Dellemijn, 2001; Hoffman et al., 2005; Hojsted & Sjogren, 2006;), and the current finding 
that 25% of participants attending an outpatient, chronic pain clinic met criteria for 
abuse or dependence on their prescription opioid medication contributes to this ongoing 
debate.  
Predicting prescription use related problems. Given that trauma and 
emotional regulation styles have been implicated in both the chronic pain and substance 
abuse literatures, it was predicted that these variables would play an important role in 
understanding the risk of prescription misuse in chronic pain patients. Specifically, it 
was hypothesized that higher reported symptoms related to trauma (i.e., higher Impact 
of Events Scale Total Scores), higher levels of alexithymia (i.e., higher Toronto 
Alexithymia Total Scores), internal conflict over sharing emotions (i.e., higher 
Ambivalence Over Emotional Expression Scale Total Scores), and lower reported 
likelihood of trying to understand, process, and express emotions (i.e. lower Emotional 
Approach Coping Scale Total Scores) would be predictive of prescription opioid misuse 
and/or prescription opioid abuse and dependence symptoms. 
Traditional factors and prescription use problems: Personal and family history of 
substance use problems has a big impact. Personal and family history of substance use 
problems were consistently linked to more problems across the three outcome 
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measures that assessed problematic prescription opioid use (i.e., Prescription Drug Use 
Questionnaire/prescription misuse, total number of abuse and dependence symptoms, 
and meeting criteria for opioid dependence). Given that personal history of substance 
use problems was the only consistent factor identified in previous research (Turk et al., 
2008), it is not surprising that this variable had a strong, direct correlation with 
prescription misuse in this study. In fact, a reported history of substance use problems 
means that the participant has already exhibited aberrant drug related behaviors that we 
are trying to predict in this study through the use of other factors (e.g., pain, emotional 
ambivalence, etc.). Although prescription opioid misuse is unique in that the drug is 
medically administered and monitored, the psychopharmacological properties of the 
medication, and thus addictive properties, are no different from opioids obtained illicitly 
and abused. Additionally, some of the participants who reported previous problems with 
substance use had a problem with opioids “off the street”. Participants who have 
already had problems with recreational opioid use, are likely at an even higher 
increased risk to misuse a medically provided opioid medication.  
It is also not surprising that family history of substance use problems was 
predictive of prescription opioid use problems.  There is strong support in the literature 
for family history as a predictor of any substance misuse because of shared genetic 
factors, instability in parental relationships, chaotic environments during childhood, and 
shared psychological and personality risk factors (Butler et al., 2004; Hojsted & Sjogren, 
2007).  Genetic vulnerability for substance use related disorders is widely accepted in 
the literature, but much of this research has focused on the risk for alcohol related 
problems (Heath et al., 1997). It has been suggested that other factors examined in this 
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study (e.g., extraversion, psychiatric symptoms, emotional regulation, etc.) may simply 
be a result of the same genetic vulnerabilities. In other words, it may be that an 
individual is genetically predisposed for extraversion or psychiatric distress, and those 
characteristics then lead to substance use problems. In addition to the genetic risks 
resulting from family history of substance use problems, it may also be that the mere 
exposure to drugs from a younger age, less parental monitoring, more distress resulting 
from a chaotic family environment, and neglect or abuse resulting from parental use of 
substances leads to younger onset of drug use and thus increased risk of future 
substance use problems. 
Despite previous evidence that psychological distress leads to increased risk of 
prescription misuse (Michna et al., 2004), there were mixed findings in the current 
study. Psychiatric distress, as measured by the Brief Symptom Inventory, was shown to 
predict prescription misuse, but not symptoms of abuse or dependence. Clinical 
impressions of depression, anxiety, or general psychological distress commonly trigger 
concerns of substance misuse in practice. Being “under stress” is something that most 
people would recognize as a warning sign for potential problematic use, resulting from a 
desire to escape the “stress.” Interestingly, psychiatric distress was not predictive of 
prescription misuse once family history of substance use problems was controlled. 
Although unexpected that psychiatric distress predicted misuse but not diagnostic 
symptoms, this may be because psychiatric distress is a temporary state (as compared 
to the personality or emotional variables examined in this study). As a temporary state, 
distress might lead only to short-term problems of misuse, and not longer-term 
problems more consistent with symptoms of abuse and dependence. 
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It is interesting to note age and gender were not associated with increased 
prescription use problems in this study, despite some previous research suggesting a 
link (Michna et al., 2004). The sample in this study was primarily middle-aged and thus 
the lack of findings for age may be due to range restriction, rather than a true lack of 
utility of age in predicting prescription misuse. Findings have suggested that individuals 
on the extremes of the age range (i.e., adolescents/young adults and the elderly) are 
most at risk for prescription misuse, and the current sample had very few individuals 
who were at those extremes. In regards to gender, despite previous research 
suggesting that men are more likely to abuse or become dependent on substances, 
recent  evidence suggests that gender differences may not exist when examining use of 
prescription opioids (Jamison, Butler, Budman, Edwards, & Wasan, 2010). In fact, 
recent research by Jamison et al. (2010) suggests that there is likely a similar rate of 
prescription misuse between genders, but the way in which it is expressed likely differs. 
For example, Jamison et al. suggest that at the symptom level, women may report more 
distress related to misuse while men might report more environmental consequences of 
their misuse. Thus, when prescription use problems were examined at the nominal level 
in the current study, misuse or no misuse, any possible gender differences were likely 
hidden. 
Pain and prescription use problems: Pain is not as important as expected. Pain 
did not play a substantial role in predicting prescription use related problems. The only 
pain related finding, was that anxiety over the experience of pain symptoms and belief 
of inability to cope with or reduce pain symptoms, were linked to a higher likelihood of 
meeting diagnostic criteria for prescription opioid dependence. It is notable that pain 
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anxiety was not related to prescription misuse (i.e., Prescription Drug Use 
Questionnaire) or total number of abuse and dependence symptoms, but this may be 
because those participants with pain anxiety were engaging in chronic overuse of 
medication consistent with a dependence diagnosis (e.g., more tolerance, inability to 
quit medication use, withdrawal symptoms, etc.) and not risky behaviors (i.e., 
prescription misuse and/or abuse symptoms).  Increased helplessness over pain 
symptoms likely leads to increased use of medication to try and reduce pain because 
patients feel incapable of managing the pain through psychological (e.g., relaxation, 
imagery, pacing) or physical (e.g., stretching, massage, etc.) means. Despite a link 
between pain anxiety and a diagnosis of prescription opioid dependence, pain anxiety 
did not predict dependence diagnosis after accounting for family history of substance 
use problems.  
Under-treatment of pain and higher pain severity have been noted as likely 
reasons for increased opioid medication use, yet there were minimal relationships found 
between pain variables and prescription use related problems in this sample. Weissman 
and Haddox (1989) opined that prescription use related problems cannot be identified in 
patients whose pain is not being treated adequately because aberrant behaviors result 
from a desire to treat the pain, rather than a desire to feel a high from the drug. It has 
further been speculated, without research support, that individuals who are using 
prescription opioids to treat pain cannot experience the “high” from the medication. 
Despite the widespread belief in Weissman and Haddox’s (1989) theory, Weissman and 
Haddox had not experimentally examined this theorized relationship of pain and 
prescription use related problems. Although the theory that under-controlled pain leads 
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to increased prescription use has continued to be widely believed, it has not been 
examined using standardized pain measures. The finding that pain played a minimal 
role in predicting prescription use related problems in the current study is unexpected, 
and likely suggests that under-treated pain may not play as large of a role in the 
prescription misuse and diagnostic symptoms as previously hypothesized. It may be 
that the presence of pain and not the severity or distress from pain matters most. Thus, 
in this sample, in which all participants were taking prescription opioids to treat some 
degree of pain, no differences should be expected. It may also be that because the 
sample of patients who participated in this study were self-selected, a biased sample of 
pain severity was created because those individuals with more severe and unmanaged 
pain are unlikely to volunteer to sit for 1.5 to 2 hours to engage in the current study.  
Social/cognitive factors and prescription use problems: Inconsistent, minimal 
findings. Within the social/cognitive predictors, the findings were inconsistent across the 
categories of prescription opioid related problems (i.e., prescription misuse, total 
number of abuse and dependence symptoms, and dependence diagnosis). The 
social/cognitive differences between prescription misuse and prescription related 
symptoms of abuse and dependence were noteworthy. The same personality factors 
did not play a role in misuse, as compared to symptoms of abuse and dependence, and 
none of these social/cognitive variables remained significant when controlling for family 
history of substance use in the regression models. Cognitive factors that warrant further 
examination are neuroticism (i.e., lower emotional stability), openness to experience, 
and extraversion. 
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Neuroticism was predictive of total number of abuse and dependence symptoms 
and dependence diagnosis, but only in the absence of controlling for other factors such 
as family history and psychiatric distress. Although neuroticism has not previously been 
identified as a predictor of prescription use problems in chronic pain patients, the finding 
is not surprising given that neuroticism has been found to have a predictive relationship 
with other substances of abuse. Neuroticism is a personality trait defined by a 
consistent, enduring tendency to experience negative emotional states, high reactivity to 
stress, and difficulty delaying gratification of desires. As with psychiatric distress, higher 
substance use in individuals that are high in neuroticism may be due to an attempt to 
escape or avoid negative internal emotional states. It is not surprising that it was not 
predictive of prescription opioid symptoms of abuse and dependence after controlling 
for psychiatric distress. Although the measure of psychiatric distress in this paper was 
aimed at current levels of psychiatric problems, those individuals who are neurotic are 
likely to rate themselves as more psychiatrically distressed at all times. After accounting 
for psychiatric distress, the relationship of neuroticism to prescription opioid symptoms 
was no longer evident.  
Openness to experience was linked only to a higher number of total abuse and 
dependence symptoms, a relationship that was not anticipated, and only existed in the 
absence of controlling for other predictors. Increased openness to experience may 
explain increased engagement in risky behaviors (e.g., driving while feeling impaired 
from use or going to school or work while feeling impaired by their prescription), as it is 
often defined as an increased need for variety and ongoing curiosity. It may be that 
openness is related to an increased willingness to experiment with medication use, 
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and/or curiosity about medication which then leads to use of higher or more frequent 
doses than prescribed. Given the lack of previous findings regarding openness and the 
limited theoretical reasons for its role in prescription misuse or use of other substances, 
replication to determine whether this finding is consistent across samples is necessary. 
Extraversion was linked only to prescription misuse, as measured by the 
Prescription Drug Use Questionnaire, and only when the role of other factors was not 
controlled. Extraversion has not been previously studied in this population, but it is not 
surprising that higher levels of extraversion are correlated with increased prescription 
misuse, as there is evidence for  the relationship of extraversion to problems with illicit 
drugs (Agrawal, Jacobson, Gardner, Prescott, & Kendler, 2004; Gorman & Derzon, 
2002). Extraverts are typically outgoing, adventurous, and depend on external stimuli for 
excitement. As a result, it has been suggested that extraverts are more likely to be 
adventurous with their willingness to experiment with drugs. Additionally, Depue and 
Collins (1999) found that at a neurological level, extraverts’ dopamine systems are more 
responsive to pleasurable stimuli. This higher reactivity of the dopamine system to 
pleasurable stimuli likely leads to a higher responsivity to the potential pleasurable 
experience of a “high” from prescription opioids, resulting in increased misuse of the 
medication. 
Emotions and prescription use problems: Emotional ambivalence is an important, 
new predictor. The emotional variables were of particular interest, and emotional 
ambivalence was the most consistent predictor of prescription opioid use related 
problems. Higher levels of internal conflict over sharing one’s emotions was linked to 
more prescription use related problems for all three outcome categories (i.e., 
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prescription misuse, total number of abuse and dependence symptoms, meeting criteria 
for prescription opioid dependence). Even after accounting for other predictors, 
emotional ambivalence remained predictive of prescription misuse and total number of 
prescription opioid abuse and dependence symptoms. This means that even if we know 
whether someone has a family history of substance use problems, emotional 
ambivalence is able to add unique information to help us predict above and beyond the 
knowledge of family history.  
Emotional ambivalence reflects ongoing internal conflict about the desire to hide 
emotions, despite external circumstances that demand disclosure, and/or regret over 
decisions to disclose feelings. As with psychiatric distress, it is likely that the ongoing 
stress resulting from emotional ambivalence motivates the individual to quell his or her 
internal experience further. For individuals high on emotional ambivalence, prescription 
opioids may provide a way to suppress his or her internal, emotional conflict as the 
prescription is readily available and many people experience a calming and/or euphoric 
effect from opioids. It is notable that the relationship between emotional ambivalence 
and prescription use related problems remained even after accounting for psychiatric 
distress. This finding suggests that the trait-like characteristic of emotional ambivalence 
is qualitatively different from the state-like measure of general psychiatric distress. The 
consistent findings, across outcomes and after controlling for other important variables 
like family history, found with emotional ambivalence suggests that it plays a more 
substantial role in the prediction of prescription misuse than general psychiatric distress. 
A higher level of alexithymia was linked to both higher prescription misuse and 
diagnosis of opioid dependence. However, alexithymia was not predictive of either 
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outcome after accounting for the role of family history of substance use problems, pain 
variables, and social/cognitive variables.  Although alexithymia might predict 
prescription use related problems in the absence of other variables, the utility of 
alexithymia is only evident in the absence of more traditionally understood predictors. It 
is not surprising that alexithymia was not predictive of prescription misuse after 
controlling for other factors because of its high correlation with general psychiatric 
distress (i.e., Brief Symptom Inventory Global Severity Index), which was controlled for 
in this study. It is likely that the link between alexithymia and psychiatric symptoms lead 
to alexithymia being redundant, and lacking utility, when psychiatric symptoms were 
present in the model.  
There were limited findings regarding trauma related symptoms. Trauma 
symptoms were only linked to prescription opioid dependence, and only in the absence 
of controlling for other factors. It may be that that trauma related symptoms are 
predictive of more severe and chronic symptoms, as measured by meeting criteria for 
opioid dependence, rather than an engagement in risky behaviors, as measured by 
prescription misuse or total number of abuse and dependence symptoms (note: abuse 
symptoms are generally categorized as risky behaviors; whereas dependence is 
generally categorized as more chronic physical, social, and personal problems). 
Individuals with a family history of substance use have consistently been found to have 
higher rates of lifetime traumas (Maker, Kemmelmeier, & Peterson, 1998; Murphy, 
Jellinek, Quinn, Smith, Poitrast, & Goshko, 1991), and the lack of findings related to 
trauma may have resulted from controlling for family history of substance use problems. 
Additionally, the rate of reported trauma experiences was high in this study, and likely 
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reflects the unique characteristics of this sample. It may be that trauma, like pain, was 
affected by a restriction in range due to the uniqueness of the sample. In a sample with 
more varied histories of trauma, in which some participants report little to no major 
traumatic life events, participants with extensive trauma histories may be qualitatively 
different from participants who have not experienced many major stressors. Although 
not reported in the results, both stress related symptoms from trauma experience (i.e., 
Impact of Events Scale) and total number of life stressors (i.e., Life Stressors Checklist) 
were evaluated and resulted in similar findings.  
An individual’s tendency to evaluate or share emotional experiences (i.e., 
Emotional Approach Coping Scale) was not predictive of any of the prescription use 
related problems. The lack of findings related to one’s tendency to share his or her 
emotional state, despite the substantial role of emotional ambivalence in predicting 
prescription use related problems, suggests that it is the conflict over expressing 
emotions (i.e., Ambivalence Over Emotional Expression), rather than the actual 
tendency or likelihood to process and share one’s emotions with others (i.e., Emotional 
Approach Coping Scale) that leads to more emotional distress and increased 
prescription misuse. In other words, it is the internal conflict and not the actual choice to 
express emotions or seek support that matters most in predicting prescription misuse.  
Summary of prescription opioid use problems. The findings clearly showed 
that personal and family history of substance abuse contribute a great deal to the 
prediction of who may be at highest risk for prescription misuse, total number of opioid 
abuse and dependence symptoms, and meeting criteria for dependence on prescription 
opioids. In a 2008 review of the literature on prescription use related problems in 
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chronic pain populations prescribed long-term opioids, it was found that the only clear 
predictor of current or future use related problems was previous history of substance 
use problems (Turk et al., 2008). Additionally, as noted earlier, most studies included in 
this literature review were based on record reviews, and thus lacked the ability to 
determine social or personal impacts of prescription use and/or misuse on patients’ 
lives. The current findings that suggest  parental history of substance use problems, 
current psychiatric symptoms (rather than psychiatric diagnoses as noted in Michna et 
al., 2004), higher levels of pain anxiety, higher levels of alexithymia, higher levels of 
extraversion, and higher emotional ambivalence may predict increased prescription 
opioid use problems expanded upon the previous research. These findings provide 
medical care providers treating chronic pain patients a wider net of risk factors that 
should be evaluated and monitored when prescribing long-term opioid medications. It is 
especially important to note that emotional ambivalence was predictive of prescription 
misuse above and beyond the roles of traditional, pain, and social/cognitive factors. 
For prescription misuse and total number of symptoms, it was found that 
emotional ambivalence was the only clear emotional predictor after controlling for more 
basic, or previously researched variables. These findings suggest that conflict or 
distress over whether or not to share internal emotional experiences, and/or feelings of 
regret over sharing (i.e., emotional ambivalence; Ambivalence Over Emotional 
Expression Questionnaire), is more important than a limited understanding of one’s 
emotions (i.e., alexithymia; Toronto Alexithymia Scale), a general tendency to choose 
not to share one’s emotions (i.e., Emotional Approach Coping Scale), or symptoms 
related to trauma. Thus, identifying participants who report distress over the potential 
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results of sharing their feelings, do not feel capable of sharing their feelings, and/or 
experience regret over times that feelings have been shared are at higher risk of 
misusing their prescription. Emotional ambivalence has previously been related to a 
lower quality of life and poorer psychological well-being (Carson et al., 2007; Lu, Uysal, 
& Teo, 2011), and it may be that these participants have a more difficult time coping 
with their chronic pain condition and the effect that it has on their lives, leading to more 
prescription opioid misuse. It may also be that individuals high on emotional 
ambivalence misuse prescription opioids to distract from a distressing internal conflict 
regarding emotional expression. None of the emotional variables evaluated in this study 
have previously been shown to have a relationship with prescription opioid use related 
problems in chronic pain patients, despite literature suggesting they are related to the 
development and maintenance of chronic pain (Ak, Sayer, & Yontem, 2004; Burba et 
al., 2006; Celikel & Saatcioglu, 2006; DeGenova et al., 1994; Leitenberg et al., 1992; 
Lumley, Neely, & Burger, 2007) and increased risk of abusing other substances 
(Handelsman et al., 2000; Pinard et al., 1996). The finding that emotional ambivalence 
was predictive of prescription misuse and total number of prescription abuse and 
dependence symptoms, even after controlling for traditional, pain, and social/cognitive 
factors is novel and provides promising evidence for the role of emotions in predicting 
aberrant prescription use.  
The current findings regarding the rate of prescription opioid use related 
problems in this population reinforces the fact that patients being prescribed long-term 
opioid treatment must be effectively and routinely screened for risk factors. It is 
important to note, that although the traditional factors can explain much of the variance 
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in this model, there are still instances in which clinicians are in the position of predicting 
whether someone might be at risk for developing a substance problem without ever 
having used previously, and/or without knowledge of their parents’ substance use. 
Thus, absence of personal or family history of substance use problems does not imply a 
complete lack of risk, and the current study began to identify additional variables that 
could help to explain what additional characteristics make someone more at risk for 
developing prescription opioid misuse problems. Although past history of substance 
abuse can provide pragmatic information to clinicians who are prescribing and 
monitoring the use of prescription opioid medications, prior history of substance abuse 
is not theoretically descriptive, and cannot explain what characteristics have contributed 
to that individual being at higher risk of developing prescription misuse problems. Prior 
history of substance abuse may be useful in a clinical setting, in informing the decision 
to prescribe or not prescribe medication; however, it does not help us to understand 
why that person is more at risk developmentally. A theoretical understanding of the 
personality characteristics, and emotional styles can contribute to increased risk could 
help inform future prevention and treatment efforts. 
Prediction of Alcohol and Cannabis Use in Chronic Pain Patients 
The second hypothesis posited that traditional/demographic, pain, 
social/cognitive, and emotional factors would be predictive of individuals who were 
using alcohol and other drugs (as evidenced by self-reported days of use during the 
past month on the SCID). Hypothesis 2 was partially supported.  
Substance use in the sample. Use of alcohol or other drugs while prescribed 
an opioid can lead to ineffectiveness of the medication in treating pain, and serious 
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health risks. Consequently, evaluation of other substance use is essential in 
understanding the full picture of risky prescription opioid use. At the time of study 
participation, the rates of meeting current criteria for abuse or dependence on the 
following substances were substantial: 14 (14%) on alcohol, 17 (17%) on cannabis, 5 
(5%) on cocaine, 3 (3%) on opioids other than their prescription, and 3 (3%) on 
sedatives. Thus, it is essential to also understand what risk factors may contribute to 
increased likelihood of using alcohol and other drugs in a chronic pain population. Given 
the small number of participants using other drugs during the past month, only alcohol 
(41; 41% of participants) or cannabis (25; 25% of participants) use during the past 
month were evaluated. Hypothesis 2 was partially supported for the continuous 
measure of days of alcohol use; however, there was no support for hypothesis 2 when 
examining the dichotomous measures of being an alcohol user or cannabis user.  
It is first interesting to note that there were higher rates of alcohol and other 
substance use in our sample than reported in previous studies (Edlund et al., 2007). 
This may be a result of the method used to assess substance use in the current study. 
Many of the previous studies reporting substance use in chronic pain patients were 
assessed using urine drug screens, rather than self-report. Urine drug screens are 
limited by the length of time which can be evaluated as many drug tests provide 
information only on the last 3-5 days of use, as compared to the full self-reported use 
history and past 30 day use report collected in this study. Additionally, the urine drug 
screens were often conducted by individuals directly involved in the patients’ care; 
therefore, there were more motivating factors in previous studies to hide other drug use, 
because in most programs drug use could lead to expulsion from the program. Given 
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the confidentiality of the current study, there were fewer motivating factors to hide 
substance use. As a result, the current study may be a better estimate of the actual 
substance use in an urban, chronic pain patient population.  
Days of alcohol use during the past month: History of substance use and 
emotional ambivalence are still important. Many of the findings for days of alcohol 
use during the past month were similar to those of prescription opioid use related 
problems. Personal and family history of substance use problems and increased 
psychiatric distress were associated with more days of alcohol use during the past 
month.  Alcohol related problems have been the primary focus of previous research 
findings that suggest a substantial role of family history in predicting increased risk of 
misuse, and thus this relationship was anticipated (Heath et al., 1997). It is again likely 
that the genetic predisposition, in addition to environmental factors through 
development (e.g., early exposure to alcohol/drugs, structure and boundaries in the 
home, attachment, etc.), put individuals at a much higher risk of developing a multitude 
of substance use and psychiatric problems. 
As with prescription opioid use related problems, pain and social/cognitive factors 
played a minimal role in predicting increased days of alcohol use during the past month. 
Pain catastrophizing was found to predict more days of alcohol use, but this relationship 
was not maintained after accounting for other factors. The link between pain and 
increased use was anticipated, based on the concept that substances may be used to 
relieve physical pain and emotional distress. As with prescription opioid use problems, it 
was again surprising that more consistent findings between pain and increased alcohol 
use were not found. It may again be that the severity of pain necessitated by being 
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referred to the chronic pain clinic sets a rather high minimum level of pain, while the 
self-selection into a study which requires sitting for 1.5 to 2 hours sets a maximum cap 
on severity of pain. It would be interesting to determine whether a similar study, 
repeated in a primary care clinic in which the minimum pain threshold for treatment is 
much lower, would still result in a lack of findings for pain as a predictor of alcohol use. 
Regarding social/cognitive factors, it was found that less agreeableness and 
higher neuroticism were predictive of more days of alcohol use. Neuroticism was only 
linked to higher days of alcohol use in the absence of other variables. Thus, the utility of 
neuroticism as a predictor of days of alcohol use only exists when family history of 
substance use and pain catastrophizing cannot be determined. Neuroticism has long 
been identified as a risk factor for problematic alcohol use (Agrawal, Gardner, Prescott, 
& Kendler, 2005; Sher, Bartholow, & Wood, 2000; Spotts & Shonts, 1984; Spotts & 
Shonts, 1991), and it is surprising that neuroticism did not predict above and beyond 
more traditionally evaluated factors in this sample. The limited findings related to 
neuroticism in this sample may be due to the way that alcohol use was operationalized 
in this study. As opposed to previous studies which have examined problematic use 
behaviors and/or diagnostic criteria for abuse or dependence on alcohol, days of alcohol 
use during the past month might not accurately capture participants who are engaging 
in problematic use. Neuroticism may be linked more directly to problematic use rather 
than frequency of use. Lower agreeableness remained predictive of increased days of 
alcohol use above and beyond the role of family history of substance use problems and 
pain. One of the two items that was used to assess agreeableness was being “critical or 
quarrelsome” and it may be that individuals who are using alcohol more often, 
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suggestive of potential alcohol use problems, rate themselves as more quarrelsome 
because they are often defending their use of alcohol, rather than low agreeableness 
leading to increased alcohol use. 
Also interesting is the finding that increased emotional ambivalence was 
correlated with increased days of alcohol use, as this has not previously been identified 
as a predictive factor for alcohol use. The finding that emotional ambivalence was linked 
to both prescription opioid use related problems and increased alcohol use suggests the 
importance of further examination of this factor as a predictor for substance use in 
general. The finding emotional ambivalence was able to predict increased alcohol use 
after controlling for family history of substance use, pain, and social/cognitive factors 
again suggests that it is internal conflict over emotional expression that is linked to 
actual substance use in a chronic pain sample. There was no support in this study for 
the role of alexithymia, ongoing distress related to trauma experiences, or the tendency 
to express emotions in predicting alcohol use. This finding lies in contrast to previous 
research on alcohol use which has found higher levels of alexithymia as predictive of 
more alcohol related problems (Handelsman et al., 2000; Pinard et al., 1996). It may 
again be a result of the way in which alcohol use was measured which resulted in an 
inaccurate picture of alcohol related problem behavior. It may also be that alexithymia 
does not play the same role in predicting alcohol use problems in a chronic pain sample 
as it does in the general population.  
Predicting use of alcohol during the past month: All you need is age. Only 
younger age was predictive of being an alcohol user. This suggests that age, in the 
absence of any other potential risk factors, can give the best picture of who might be 
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using alcohol while receiving prescription opioids. Despite lacking participants on the 
extremes of the age range (i.e., no adolescent and few elderly patients), it still seems 
that even a few years difference in age can predict the likelihood of being a current 
alcohol user. In fact, knowing only age led to the correct classification of almost 3/4s of 
patients as current alcohol users in this study. As alcohol is often used socially, it may 
be that younger patients are more likely to drink at least once per month because of the 
increased social demands to drink often associated with younger age. Additionally, 
younger individuals have less occupational and family demands and are therefore more 
able to drink without consequences resulting from ignoring those demands. 
The reason for differences between the hierarchical regression of days of alcohol 
use, versus the categorical decision of whether or not someone is an alcohol user, may 
be due in part to the fact that someone who uses alcohol one or two days per month, 
likely looks very different from someone who is using 15 or 30 days per month. In the 
categorical model of alcohol user versus non-user, participants who used alcohol one 
day during the last month were lumped into the same group as regular or daily users. 
Predicting use of cannabis during the past month: All you need is age. 
Surprisingly, the only clear predictor of being a current cannabis user was being 
younger. This finding suggests that it is imperative to be aware of increased risk of 
younger chronic pain patients to be using illicit drugs, and cannabis in particular. This 
finding also suggests that regardless of having other characteristics that had been 
hypothesized as being predictive of illicit drug use, we may only need to know age to 
know who needs to be monitored more closely for illicit drug use while receiving long-
term opioid treatment for chronic pain. Perhaps younger patients at a chronic pain clinic 
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are more likely to have more active social lives, which lead to more availability of illicit 
drugs that are not as easily accessed by older patients.  
Methodology Differences in Data Collection 
As this study shows, aberrant prescription use and use of alcohol and other 
drugs while taking prescription opioids are a substantial risk in chronic pain populations, 
and there is an obvious need to be able to collect accurate information about these 
behaviors from patients. Appropriate patient care and targeting of monitoring 
interventions is limited by the accuracy of information received, and there are very real 
and serious health risks associated with these problematic behaviors. Typical medical 
care relies upon a mix of patients’ self-reports and clinical providers’ impressions of the 
patients. It is especially difficult to gain accurate information regarding prescription 
misuse and alcohol and other drug use when there are strong motivating forces for 
patients to hide their use from their medical care providers. A patient’s disclosure that 
he or she is misusing a prescription or using other substances may lead to restrictions 
of their opioid medications and/or being removed from the treatment program. Thus, 
efforts to continue to improve the methods used to improve the accuracy of patients’ 
self-reports are necessitated.  
Based on findings from a previous study conducted by Sander et al. (2008) which 
examined methods for improving trauma disclosure in a college population, it was 
predicted that the enhanced assessment method would lead to more disclosure of 
trauma, prescription misuse and abuse/dependence symptoms, and alcohol and other 
drug use than a standard interview assessment method and a written assessment 
method. Based on findings by Newman et al. (2002), which examined self-reported 
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substance use and risky HIV related behaviors and found that the more distance from 
the other person (e.g., computer is better than phone, phone is better than in-person), 
the more reported risky behaviors, it was predicted that the written assessment group 
would disclose more problematic behaviors than the standard interview assessment 
method. It is important to note that in this study it was assumed that reports of more 
misuse of prescription medications, higher number of abuse and dependence 
symptoms on prescription opioids, more frequent use of substance use, or higher 
number of reported traumas and trauma symptoms are considered to be more accurate 
information because of the usual bias for individuals to minimize these responses. 
Hypothesis 3 was partially supported. In contrast to hypothesis 1 and 2, hypothesis 3 
was examined through an experimental design, employing random assignment to the 
assessment groups. The experimental design allows the interpretation that any 
assessment group differences found were likely due to the group assignment. 
As predicted, the enhanced assessment method group reported more abuse and 
dependence symptoms on their prescription opioids than the written group; however, no 
differences were found between the standard interview assessment group and the 
written group. Thus, the enhanced techniques of meta-communication, further 
questioning of participants’ responses, and normalizing problematic behaviors may 
have led to participants’ greater likelihood to share problematic symptoms related to 
their prescriptions. Interestingly, no group differences existed for prescription misuse as 
measured by the Prescription Drug Use Questionnaire. Questions of misuse are less 
stigmatizing than symptoms of abuse and dependence, and it may be that no 
differences were found between groups because there was not as much motivation for 
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participants in any of the groups to minimize their responses. Future exploration of this 
hypothetical explanation is necessary, but if supported this may suggest that it would be 
more efficient to question participants on misuse behaviors than symptoms of abuse or 
dependence because no specialized assessment method is necessitated. 
Unexpectedly, there were no differences in reported days of alcohol use or 
symptoms of abuse or dependence on alcohol. This finding may also be attributed to 
the fact that alcohol use is a relatively socially acceptable behavior and participants 
across all three groups may have had no motivation to minimize their use or behaviors 
related to alcohol. As predicted, there were group differences in regards to cannabis 
use, but as with prescription use, the differences were found only with self-reported 
symptoms of abuse and dependence on cannabis, and not the less stigmatizing report 
of use. Specifically, the enhanced group reported more cannabis related abuse and 
dependence symptoms than the written group. Surprisingly, the standard interview 
assessment group also reported more cannabis abuse and dependence symptoms than 
the written group. Thus with cannabis use, participants were more likely to report 
symptoms of abuse and dependence when interviewed, rather than when asked to 
respond to a written questionnaire. This finding is in contrast with Newman et al.’s 
(2002) finding that more distant methods of disclosure lead to higher reports of 
stigmatizing behaviors.  
Finally, there were inconsistent results regarding trauma. It was found that as 
predicted, the enhanced group shared marginally more trauma related symptoms on the 
Life Stressors Checklist than the written group (no difference existed between either 
enhanced or written and the standard group). In contrast, the written group disclosed 
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higher current distress over their traumatic experiences as measured by a 1 to 5 scale 
than the standard group (no difference existed between the written or standard group 
and the enhanced group). Taken together, these findings regarding trauma symptoms 
and distress suggest that the enhanced group was more consistently related to higher 
report of trauma and importantly symptoms related to trauma, but that the addition of a 
written scale rating distress may be useful. It may be that the distress rating scale was 
better understood and conceptualized when participants could actually look at the 
anchors of “no distress” to “extremely distressed”. It is also worthwhile to note that the 
standard group was not particularly effective in gathering trauma related symptoms.  
These findings are important because they stand in contrast to the standard 
interview techniques commonly methods in medical settings. This suggests that it is 
important that continued efforts are made to evaluate and improve interviewing styles, 
and that there is promise for engaging in meta-communication, normalizing of 
problematic behaviors, and persistent questioning and following of openings in patients’ 
responses to yes/no questions. It is also essential that efforts are made to make these 
methods marketable to and useful for busy chronic pain medical treatment providers. 
Considerations of appropriate training in these techniques would be essential to 
effective use of the enhanced strategies. Additionally, given the extra time needed to 
employ the enhanced techniques, it may be useful to target the use of these techniques 
to patients who are high on at least one of the predictive variables identified in 
hypotheses 1 and 2.  
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Limitations 
 One limitation of this study was that it was based fully on self-report. Self-report 
can be biased because retrospective reporting is subject to a participant’s ability to 
remember days of use or occurrence of symptoms, as well as potential motivations to 
actively withhold information (e.g., stigmatizing, guilt, worries about the consequences 
of sharing aberrant behaviors, etc.). Given the sensitive nature of the questions asked in 
this study, it is likely that many participants experienced some hesitance to share 
accurate information about aberrant prescription opioid use, use of alcohol or other 
drugs, and trauma histories. Additionally, almost all of the self-report was conducted via 
questionnaires, which can be limited by the participants’ ability to understand and 
accurately respond to questions and rating scales. Thus, although efforts were made to 
improve the validity of participants’ self-reports through ensuring confidentiality, 
anonymity, and the researchers’ presence throughout the study to answer any 
questions the participants had, the accuracy of the information cannot be ensured. Also, 
at a very basic level, study participation was based on the self-report of the participant 
that he or she was a current client of the pain management clinic and had been 
prescribed an opioid for longer than 3 months. Unfortunately, given the need for 
anonymity, the researchers had to base their decision on whether the individuals 
qualified for the study on participants’ self-report and the researchers’ own judgment of 
whether or not the potential participant was being honest.  
The current study was also limited by the study design which used a point 
prevalence model to examine the correlations between potentially risky personal 
characteristics and current problematic use at a single time point. The current study 
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design does not exclude the possibility that problematic prescription use has some 
influence on personality or emotional factors and thus rather than being predictive of 
future misuse, the identified characteristics may simply be a signal of current 
problematic use. For example, it could be that current prescription misuse leads to more 
conflict over emotional expression rather than the reverse. Importantly, because this 
study was not longitudinal, interpretations of the results of this study are unable to 
answer the questions of whether or not an individual should or should not be prescribed 
opioid medications and who will abuse their medications. As a result, we were only able 
to identify variables that are likely descriptively useful in understanding people who 
might misuse prescriptions and to determine whether these factors (e.g., emotional 
ambivalence, personality factors) actually lead to increased misuse, a prospective study 
must be conducted. 
 Another major limitation of this study was that participants self-selected to 
participate. Recruiters actively tried to engage with any patient who entered the waiting 
room during recruitment periods and brochures were available to all patients, there may 
still be unique factors about those participants who were willing to participate in a study 
about substance use, trauma, and prescription use. It may be that the individuals who 
self-selected into the study were more comfortable sharing aberrant prescription use 
and/or substance use. It may also be that participants who had even more misuse of 
their prescriptions or more substance use chose not to participate because of fears over 
the potential consequences despite the guaranteed anonymity. Further, it may be a 
healthier sample that self-selected into the study, because participants with more 
severe pain conditions may have felt incapable of sitting in a study session for up to 2 
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hours. Given that medical record reviews were not conducted on the full clinic 
population, it is unclear how this self-selected sample might compare to the entire 
chronic pain management clinic. 
 This study was also limited by the inability to consult with the participants’ 
treatment providers or use medical records. Unfortunately, because of the IRB issues 
related to maintaining the anonymity of the participants, we were unable to collect 
participant names to be able to match up doctors’ ratings or access medical records. 
Having access to the medical records would have allowed verification of self-reported 
aberrant behaviors such as requesting another prescription before the previous one 
should have ended, requesting frequent dose increases, requesting shorter acting or 
more commonly abused opioid medications, etc. Having access to the medical records 
also would have allowed for exploration of the physicians’ recorded concerns about 
patients’ potential for aberrant behavior.  
Finally, the results of this study likely only generalize to patients receiving long-
term opioid prescriptions for chronic pain who are being treated in an urban, low-income 
pain management clinic. Additionally, the majority of the participants were African-
American which likely contrasts from ethnic make-up of many chronic pain management 
clinics. It is unclear based on this single study whether the results would be consistent 
in a primary care treatment center, in clinics treating patients primarily of other 
ethnicities, or in clinics treating non-urban or middle to higher income patients. Also, 
given that the identification of emotional ambivalence is a novel finding, replication of 
this study is warranted to ensure the finding was not erroneous or sample specific. 
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Future Directions  
 Future studies should employ longer-term tracking of chronic pain patients to 
improve our understanding of who develops problems with aberrant prescription opioid 
use, symptoms related to prescription opioid use, or concurrent use of alcohol and other 
substances. Given the point in time strategy design of the current study, the direction of 
the relationships between those variables termed for study purposes as predictors and 
those termed as outcomes are unknown. A point in time strategy is often used in early 
research on a topic, but the next step is to evaluate and track the identified personal 
characteristics that may signal potential problematic future use beginning at the initiation 
of long-term opioid treatment.  
The focus of most of the research in this area has examined either individuals 
who were receiving care through pain management clinics or those seeking treatment in 
an opioid management setting (e.g., methadone clinic); however, the rate of prescription 
misuse in individuals receiving pain medication through primary care is even less 
understood. Given the lower degree of monitoring due to time constraints and limited 
experience and training with a chronic pain population, there may be increased risk of 
aberrant medication related behavior in a primary care setting. It is additionally 
important to consider the use of opioid medications in a primary care setting as patients 
receiving treatment through primary care likely constitutes a large proportion of 
prescriptions for opioid treatment. 
Future studies should also evaluate physicians’ ratings of how likely they believe 
their patients are to be misusing their prescription medication, meeting criteria for abuse 
or dependence on their prescription opioid, and using alcohol and illicit substances 
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along with their prescription opioid would add substantially to the understanding of how 
decisions about patients are made in actual practice. Current practice guidelines 
suggest that a thorough evaluation of risk for aberrant prescription opioid use is 
conducted at the beginning of all patients’ treatment programs (Chou, Ballantyne, 
Fanciullo, Fine, & Miaskowski, 2009a; Chou et al., 2009b), but given the weak evidence 
cited in those guidelines for any particular characteristics that define risk, it would be 
useful to understand how risk assessment is currently being practiced. This would allow 
a baseline for understanding how accurate doctors are in making decisions about who 
is at risk of future problematic prescription use and/or who is currently engaging in 
problematic use behaviors. Further, understanding where potential gaps between 
research evidence for risk factors and providers’ knowledge could help inform needs for 
further dissemination of findings to physicians treating chronic pain patients with long-
term opioid treatment. 
Future studies should evaluate both self-report methodologies and biological 
markers of alcohol and drug levels. Employing both self-report and biological markers 
would allow a reference point for accuracy in self-reported use. Although this would 
strengthen the faith in the outcome measures to the predictive models, this would be 
especially important for improving our understanding of which methodological 
assessment groups produced the most accurate reports of use. In the current study, the 
possibility that participants in the enhanced group were exaggerating their use rather 
than being more comfortable sharing prescription abuse and dependence symptoms, 
although unlikely, is left open.  
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The results of this study suggest that emotional styles contribute uniquely to the 
prediction of prescription opioid use related problems as well as increased days of 
alcohol use. In particular, these findings warrant further examination of emotional 
ambivalence and alexithymia to determine whether the findings in this study can be 
replicated. The findings of this study also suggest that it is internal conflict rather than 
actual actions related to emotional expression that can be predictive of prescription 
misuse and use of alcohol while taking prescription medication. Therefore, it may be 
useful to further explore whether conflict over addressing problems in relationships 
and/or the internal experience of active attempts to avoid experiences which may elicit a 
need to decide whether to express oneself. The ultimate goal of identifying risk factors 
is to integrate assessment of those risks into clinical practice. It is imperative to develop 
methods that can quickly and routinely assess these emotional risk factors. Given that 
observational and interview techniques are the predominant method of data collection in 
a clinic setting, it will be essential to develop similar means for assessing emotional 
styles.  
 Most importantly, further research and development must be done on the 
techniques that can be employed to prevent the development of problematic 
prescription opioid use in chronic pain populations after identifying patients who are at-
risk for problematic use. There are four main areas of intervention that have been 
identified recently in the literature: a) monitoring through random drug screens and 
continued evaluation with the treatment provider for signs of aberrant use  (Bailey, 
Hurley, & Gold, 2010; Chou et al., 2009a; Jamison et al., 2010; Markowitz, Francis, & 
Gonzales-Nolas, 2010; Webster & Fine, 2010); b) medication based changes (e.g., 
131 
 
changing the pharmaceutical makeup of the medication to make it tamper proof, 
providing only long-acting opioids to clients who are identified as higher risk, providing 
only scheduled dosing of medications with no “as needed” dosing; Bailey, Hurley, & 
Gold, 2010; Walwyn, Miotto, & Evans, 2010; Webster & Fine, 2010); c) contracting for 
appropriate medication use (Bailey, Hurley, & Gold, 2010; Markowitz, Francis, & 
Gonzales-Nolas, 2010); and d) psychological interventions, including psycho-
educational and cognitive-behavioral techniques focused on the interaction of pain and 
addiction (Jamison et al., 2010). These forms of intervention are relatively new and not 
well studied in this population. In fact, as mentioned previously, the current practice 
guidelines suggest that although it is extremely important to monitor, track, and 
intervene with patients who are at-risk or actively engaging in aberrant use, a clear 
understanding of what “at-risk” is and how effective these intervention techniques are at 
preventing aberrant medication behavior is lacking. Additionally, given the identification 
of emotional ambivalence as an identified risk factor in the chronic pain population, 
further efforts should be made to develop and integrate emotionally-focused treatment 
approaches into the psychological interventions. 
Summary  
 This study at the most basic level provided another sampling of the rate of 
problematic prescription opioid use in chronic pain patients. Previous rates of 
problematic prescription use have ranged from 0 to 50% (Hojsted & Sjogren, 2006). The 
wide ranges of previously reported rates are based on both inconsistent definitions of 
problematic prescription use as well as variations in study methods. Given that the 
current study assessed problematic prescription use using two definitions (i.e., 
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prescription misuse as measured by the Prescription Drug Use Questionnaire and 
number of symptoms of DSM-IV-TR abuse and dependence symptoms) and found that 
approximately a quarter to a half of participants were displaying some form of 
problematic prescription opioid use is likely a better estimate of the actual problematic 
use in a chronic pain population prescribed long-term opioids. 
It is also significant that this study replicated the findings that past history of 
abuse of substances and/or family history of abuse of substances are predictive of 
prescription misuse (Turk et al., 2008). This finding provides stronger evidence that 
patients receiving opioid medications need to be screened for previous substance 
abuse and family substance use. In addition to reinforcing and replicating the role of 
personal and family history of substance use problems, this study sought to explore 
theoretical factors that may contribute to understanding and describing the development 
of prescription opioid dependence. To this end, this study provided new evidence for the 
role of emotional ambivalence as a risk factor for prescription misuse, prescription 
abuse and dependence symptoms, and alcohol use. Previous research has shown a 
relationship between emotional ambivalence and other deleterious outcomes such as 
poorer psychological health, poorer coping with pain, and increases in other negative 
physical symptoms (King & Emmons, 1990). Therefore, ambivalence over emotional 
expression likely plays an important role in both predicting problematic prescription use 
and predicting poorer treatment outcomes for chronic pain. This study also provided 
new evidence for the potential role of personality factors in identifying participants with 
problematic prescription opioid use; however, inconsistent findings suggest a need for 
further research in this area. 
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 Awareness of risk factors for prescription misuse can inform clinical practice by 
those medical providers involved in the treatment of a patient with a chronic pain 
condition. Specifically, early assessment of risk could help to identify patients who 
should be more closely monitored and/or provided an intervention focused on 
preventing problematic prescription use and use of alcohol and other drugs. Cost and 
time limitations make it unlikely that intensive monitoring and intervention efforts could 
be provided to all patients, thus honing in on the most risky personal characteristics is 
imperative in providing these services. There is a clear need to continue to improve our 
understanding of the risk factors that need to be monitored in patients receiving long-
term opioid treatment for chronic pain, as well as improvement of clinical assessment 
methods to gain accurate reports of problematic prescription use and use of alcohol and 
other substances. There is also an evident need based on findings from the current 
study to continue to focus efforts on understanding the role of personality factors and 
emotional ambivalence in the development of problematic prescription opioid use in 
chronic pain patients. Finally, there is also evidence that further development in 
assessment methods, focused on understanding the role of meta-communication, 
normalizing of problematic behaviors, and probing unclear responses, could lead to 
better identification of patients already engaging in problematic prescription related 
behaviors. Further understanding of role of these techniques, as well as dissemination 
of these techniques to frontline treatment providers is suggested. 
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Appendix A – Recruitment Brochure 
Research Study: Chronic Pain, 
Emotions, and Prescription Use 
 
 
 
 
 
 
 
 
 
 
 
_______________________________ 
 
Evaluating Prescription and Drug Use Patterns 
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Who is eligible? 
We are seeking: 
● Adults who are attending the University Pain Clinic for management of a chronic pain disorder, 
such as fibromyalgia, myofascial pain, irritable bowel syndrome, low back pain, chronic pelvic 
pain, headaches, bladder pain, or other pain problems.  
● We are looking for participants who have been taking opioid medications such as Vicodin, 
Tylenol 3’s or 4’s, or other pain killers for at least 3 months. 
 
 
 
How the study works 
The study calls for a single session evaluation of your pain, physical health, and psychological 
functioning.  The evaluation can be completed at convenient locations on the Wayne State campus 
or at the Detroit Medical Center. 
Participation in the single session will take approximately 1 ½ hours of your time.   
The evaluation will include questionnaires and possibly an interview. You will be asked about your 
pain, health, stress, and your pattern of prescription use.  
How do I participate? 
You can find out more information about this study by contacting Lindsay Oberleitner at 313-577-
2773. She can provide you with more information about the study and set up a convenient time to 
meet you at the Wayne State campus or at the Detroit Medical Center. 
 
Compensation 
We will pay you for your time.  You will be paid $30 immediately after completing the study visit.   
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Wayne State University 
 
 
 
Investigator: 
Mark A. Lumley, Ph.D. 
Department of Psychology 
Wayne State University 
Todd Lininger, M.D. 
University Pain Clinic 
 
 
Research Personnel:  
Lindsay Oberleitner 
Kathryn Zumberg 
Amy Loree 
 
For more information   about this study, please contact the 
research team: 
 (313) 577-2773 
 
 
Or visit our website: 
http://clas.wayne.edu/healthlab/ 
 
and click on the Current Studies link   
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Appendix B – Telephone Script 
 
Telephone Script for Substance Abuse in Chronic Pain 
 
Hello <insert patient’s name>, my name is _________ and I’m calling from Wayne State 
University.  I’m returning your call regarding interest in our chronic pain and medication use 
study. You said you were interested in learning more about a study that we are doing of chronic 
pain and medication use.   
 
Do you mind if I ask you a few quick questions regarding your treatment? How long have you 
been prescribed a pain medication? What medication are you currently prescribed? 
(if they have been taking an opioid for 3mos continue with choice 1, if not follow to choice 2) 
1. We hope that you are open to meeting, learning more about the study, and possibly 
participating.  May we set up your appointment now? 
2. Thank you for your interest in our study. Unfortunately you do not meet the requirements 
for our study as you need to have been taking an opioid pain medication for at least 3 
months. If you are still interested in <insert time until they reach 3 months> please give 
us a call and we would be happy to schedule a visit with you. 
 
Can I tell you briefly about this project?  If you are interested, we can set up an appointment to 
go over the details and the consent form. 
 
This study is designed to evaluate medication use, alcohol and other substance use patterns in 
chronic pain patients and how a variety of factors such as severity of pain, coping with pain, 
ways of thinking, and ways of dealing with emotions. 
 
If you participate, we would need to meet at the University Pain Clinic or the Simon’s Building 
at Wayne State for about 1 ½ for an assessment of the various factors I just described to you. 
Most of these are questionnaires that you will complete, but we may also do an interview.  
 
We are going to pay you for your time.  We will give you $30 right when you finish the session.  
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Appendix C – Information Sheet 
 
Research Information Sheet 
 
Title of Study: Medication and Drug Use in Patients with Chronic Pain 
 
Principal Investigator (PI):  Mark A. Lumley, Ph.D. 
     Department of Psychology 
     Wayne State University 
     313-577-2773 
 
Purpose 
 
You are being asked to be in a research study of factors related to medication and substance use 
among people who have chronic pain.  You are being asked to be in this study because you have 
a chronic pain condition and have been prescribed a medication for your pain for at least 3 
months. This study is being conducted at Wayne State University and will enroll approximately 
120 participants. Please read this form and ask any questions you may have before agreeing 
to be in the study. 
 
In this research study, we are trying to understand patterns of prescription medication use in 
patients who are being treated for chronic pain. The goals of this research are to learn: 
a) how frequently prescription medication is misused and other substances (for example, 
alcohol or marijuana) are used by people with chronic pain; 
b) what characteristics of people are related to misusing medications or using substances; 
c) how much people report when they complete questionnaires or are interviewed.  
 
Study Procedures 
 
If you agree to take part in this research study, you will be asked to complete a number of 
questionnaires about your pain, functioning, mood, personality, and feelings.  You will then be 
asked either to talk with an interviewer or to complete questionnaires about possible traumatic 
and experiences that you may have had, your use of alcohol and other substances, and your use 
of your prescription medication. Which format (questionnaires or interview) you have will be 
determined randomly (like by a flip of a coin); you have a 2 in 3 chance of being interviewed, 
and a 1 in 3 chance of completing the questionnaires.  Finally, you will be asked to demonstrate 
how you might communicate different feelings to someone, such as being assertive, or telling 
someone that you care.  This communication exercise will be audiotaped.  The entire session will 
take about 1 ½ hours. 
 
Benefits  
 
As a participant in this research study, there may be no direct benefit for you; however, 
information from this study may benefit other people now or in the future.  
 
Risks  
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By taking part in this study, you may experience the following risks: sharing personal 
information about your prescription drug use, other substance use, and/or history of trauma may 
be briefly upsetting or uncomfortable.  In addition, you risk the loss of confidentiality under any 
of the following conditions: If you are thought to be at risk for self-harm or harming another, 
then this information may be released. If at any time during the study there is a concern that child 
abuse or elder abuse has possibly occurred, then this information must be released to the 
appropriate authorities. If at any time during the study there is a disclosure of illegal criminal 
activities, illegal substance abuse, or violence, this information may be released to the 
appropriate authorities. If at any time during the study it is discovered that you have a reportable 
communicable disease (certain sexually transmitted diseases and/or HIV), then this information 
must be released to the public health department. There may also be risks involved from taking 
part in this study that are not known to researchers at this time. 
 
Study Costs and Compensation 
 
Participation in this study will be of no cost to you.  For taking part in this research study, you 
will be paid for your time and inconvenience.  You will receive $30 for completing the single 
session. Payment will be received in the form of cash immediately following completion of your 
study session.  
 
Confidentiality 
 
You will be identified in the research records by a code name or number. There will be no list 
that links your identity with this code. 
 
Voluntary Participation /Withdrawal 
 
Taking part in this study is voluntary. You are free to not answer any questions or withdraw at 
any time. Your decision will not change any present or future relationships with Wayne State 
University or its affiliates or other services you are entitled to receive. 
 
Questions 
 
If you have any questions about this study now or in the future, you may contact Mark Lumley, 
Ph.D. or one of his research team members at the following phone number, (313) 577-2773. If 
you have questions or concerns about your rights as a research participant, the Chair of the 
Human Investigation Committee can be contacted at (313) 577-1628. If you are unable to contact 
the research staff, or if you want to talk to someone other than the research staff, you may also 
call (313) 577-1628 to ask questions or voice concerns or complaints. 
 
Participation: 
By completing the questionnaires, possible interview, and communication exercise you are 
agreeing to participate in this study. 
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Appendix D – Session Scripts 
 
Script for Standard Interview 
 
At the start of predictor portion 
I am going to have you start by filling out some questionnaires about your family history, your 
personality, and your typical way of dealing with emotions.(FLIP THROUGH THE PACKET) As 
you can see, the scale will change as you go from scale to scale so please look carefully at the 
instructions at the top of each page. If there are any items that you have questions about, please 
feel free to ask me at any point or put a mark near it so that you can ask me about it later. Do 
you have any questions? 
 
At the start of randomized portion 
First introduce the task:  
Now I am going to go through a variety of questions about difficult experiences you may have 
had, substance use and prescription use with you with you. We know that remembering when a 
symptom started and how regularly it occurred can be difficult to remember, so please just try 
your best to give the most accurate response you can.  
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Meta-Communication Script for “Enhanced Group” 
 
At the start of predictor portion 
I am going to have you start by filling out some questionnaires about your family history, your 
personality, and your typical way of dealing with emotions.(FLIP THROUGH THE PACKET) As 
you can see, the scale will change as you go from scale to scale so please look carefully at the 
instructions at the top of each page. If there are any items that you have questions about, please 
feel free to ask me at any point or put a mark near it so that you can ask me about it later. Do 
you have any questions? 
 
General Approach Throughout Facilitated Portion: 
• Focus on being “warm” toward the participant 
• Make a conscious effort to not show shock or surprise at participant’s responses 
• Have a good knowledge of substances, quantities, methods of use so that the participant 
feels like you are knowledgeable and interested 
• Use their first name and make sure they are comfortable and relaxed (make sure you 
appear comfortable and relaxed also by body language and voice) 
 
At the start of randomized portion 
First introduce the task:  
We are going to go through a variety of questions difficult experiences you may have had, 
substance use and prescription use with you. We know that remembering when a symptom 
started and how regularly it occurred can be difficult to remember, so please just try your best to 
give the most accurate response you can.  
 
Meta-communicate about comfort sharing  
I know that many of these questions can be difficult to share and they might be questions that you 
are not normally comfortable sharing with other people in your life. 
 
It is normal to feel somewhat uncomfortable sharing information about really difficult 
experiences in your life or about your use of alcohol, other substances, or about misusing your 
prescription medication.  
 
How are you feeling about sharing with me today? 
 
What are your concerns about sharing with me today? 
 
Discuss confidentiality in detail 
Do you have any concerns about confidentiality that you would like to discuss? 
 
I know that your prescription use and substance use might be an especially sensitive topic 
because of concerns that other people, especially your doctor or the staff at the pain clinic might 
find out about your response. I wanted to let you know again that I will not be sharing any of this 
information with other people at the clinic or anyone else.  
 
Normalize the experience of some of the symptoms 
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I also want you to know that many people have experienced some of these symptom 
 
Discuss the importance of honest answers 
I also want you to know how important accurate answers are for this project. Your answers will 
help us with determining who is most likely to be experiencing problems in the treatment of their 
chronic pain. It may also help us to understand  
 
At the beginning of the prescription drug portion 
We are about to start the portion of the interview dealing with your use of your prescription pain 
medication. I want you to know again that this information is confidential and also that many 
people have used their prescriptions in ways other than how they are prescribed, and that many 
people might also notice that they are having some problems or consequences from their use. 
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Appendix E- HIC Approval 
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There are currently few factors guiding physicians’ decisions as to whether an 
individual patient may need additional regulation of pain medications because of risks. 
The limited predictive factors applied to prescription opioid abuse in chronic pain 
patients is surprising given the breadth of personal, cognitive, and emotional factors 
explored in both chronic pain and substance abuse literatures broadly. The present 
study had two purposes. First, concurrent risk factors for prescription misuse and 
substance abuse in chronic pain patients were explored, specifically examining whether 
the addition of emotional factors to the traditionally used risk factors improves prediction 
of prescription and substance misuse. The present study also experimentally examined 
whether an enhanced interview condition would lead to increased disclosure of 
prescription misuse, other drug use, and traumatic events, by normalizing the 
experience of substance use and trauma, and engaging in a conversation about 
confidentiality of the information. Participants completed one session in which they were 
assigned to report their prescription misuse, substance use, and trauma in one of the 
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following formats: written/private, standard interview, enhanced interview. In the 
enhanced condition, the interviewer followed an initial script addressing participants’ 
potential concerns about disclosure prior to questions regarding substance use and 
trauma. In addition to replicating the role of personal and family history of substance use 
problems, this study provided new evidence for the role of emotional ambivalence as a 
risk factor for prescription misuse, prescription abuse and dependence symptoms, and 
alcohol use. Interestingly, only younger age was predictive of cannabis use. This study 
also provided evidence that further development in assessment methods, focused on 
understanding the role of meta-communication, normalizing of problematic behaviors, 
and probing unclear responses, could lead to better identification of patients already 
engaging in problematic prescription related behaviors. 
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